Mildly	O
oxidized	O
low-density	B-protein
lipoproteins	I-protein
decrease	O
early	O
production	O
of	O
interleukin	B-protein
2	I-protein
and	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
binding	O
to	O
DNA	O
in	O
activated	B-cell_type
T-lymphocytes	I-cell_type
.	O

Activated	O
T-lymphocytes	O
are	O
found	O
early	O
in	O
atherosclerosis	O
lesions	O
,	O
but	O
little	O
is	O
known	O
about	O
their	O
role	O
.	O

Oxidized	O
low-density	B-protein
lipoproteins	I-protein
(	O
oxLDLs	B-protein
)	O
are	O
considered	O
to	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
the	O
lesions	O
,	O
and	O
we	O
have	O
previously	O
demonstrated	O
that	O
oxLDLs	B-protein
inhibit	O
not	O
only	O
interleukin	B-protein
(	I-protein
IL	I-protein
)	I-protein
-2-receptor	I-protein
expression	O
on	O
the	O
surface	O
of	O
in	O
vitro-activated	O
T-lymphocytes	O
but	O
also	O
their	O
proliferation	O
.	O

We	O
have	O
now	O
investigated	O
the	O
effect	O
of	O
oxLDLs	B-protein
on	O
blast	O
differentiation	O
,	O
on	O
IL-2	B-protein
synthesis	O
and	O
on	O
the	O
activation	O
of	O
the	O
nuclear	B-protein
factor	I-protein
kappaB	I-protein
(	O
NF-kappaB	B-protein
)	O
system	O
in	O
activated	O
lymphocytes	O
.	O

Mildly	O
oxLDLs	B-protein
(	O
50	O
and	O
100	O
microgram/ml	O
)	O
decreased	O
the	O
number	O
of	O
lymphoblasts	B-cell_type
and	O
the	O
level	O
of	O
IL-2	O
concentration	O
in	O
the	O
culture	O
supernatants	O
after	O
activation	O
of	O
lymphocytes	B-cell_type
by	O
phytohaemagglutinin	B-protein
and	O
PMA+ionomycin	O
.	O

The	O
inhibition	O
of	O
IL-2	B-protein
production	O
was	O
observed	O
in	O
the	O
CD3	B-protein
(	O
+	O
)	O
T-lymphocyte	O
cytoplasm	O
as	O
early	O
as	O
4	O
h	O
after	O
activation	O
by	O
PMA+ionomycin	O
.	O

The	O
study	O
of	O
NF-kappaB	B-protein
showed	O
that	O
oxLDLs	B-protein
led	O
to	O
a	O
decrease	O
of	O
activation-induced	B-protein
p65/p50	I-protein
NF-kappaB	B-protein
heterodimer	O
binding	O
to	O
DNA	O
,	O
whereas	O
the	O
presence	O
of	O
the	O
constitutive	O
nuclear	O
form	O
of	O
p50	B-protein
dimer	I-protein
was	O
unchanged	O
.	O

This	O
was	O
correlated	O
with	O
an	O
unchanged	O
level	O
of	O
the	O
active	O
form	O
of	O
the	O
cytosolic	B-protein
inhibitor	I-protein
protein	I-protein
IkappaB-alpha	B-protein
.	O

Taken	O
together	O
,	O
these	O
observations	O
suggest	O
that	O
the	O
immunosuppressive	O
effect	O
of	O
oxLDLs	B-protein
might	O
operate	O
via	O
a	O
dysregulation	O
of	O
the	O
T-lymphocyte	B-cell_type
activation	O
mechanisms	O
.	O

Biochem	NULL
.	NULL

J	NULL
.	NULL

(	NULL
1999	NULL
)	NULL
337	NULL
,	NULL
269-274	NULL
(	NULL
Printed	NULL
in	NULL
Great	NULL
Britain	NULL
)	NULL
269	NULL
Mildly	NULL
oxidized	NULL
low-density	NULL
lipoproteins	NULL
decrease	NULL
early	NULL
production	NULL
of	NULL
interleukin	NULL
2	NULL
and	NULL
nuclear	NULL
factor	NULL
xB	NULL
binding	NULL
to	NULL
DNA	NULL
in	NULL
activated	NULL
T-lymphocytes	NULL
Sylvie	NULL
CASPAR-BAUGUIL*	NULL
,	NULL
Jean	NULL
TKACZUKt	NULL
,	NULL
Marie-José	NULL
HAURE*	NULL
,	NULL
Martine	NULL
DURANDt	NULL
,	NULL
Julie	NULL
ALCOUFFE*	NULL
,	NULL
Mogens	NULL
THOMSEN®*	NULL
,	NULL
Robert	NULL
SALVAYRE*	NULL
and	NULL
Hervé	NULL
BENOIST*®	NULL
*INSERM	NULL
U	NULL
466	NULL
,	NULL
Institut	NULL
Louis	NULL
Bugnard	NULL
,	NULL
CHU	NULL
Rangueil	NULL
,	NULL
31403	NULL
Toulouse	NULL
Cedex	NULL
4	NULL
,	NULL
France	NULL
.	NULL

and	NULL
fLaboratoire	NULL
d'Immunologie	NULL
,	NULL
CHU	NULL
Rangueil	NULL
,	NULL
31403	NULL
Toulouse	NULL
Cedex	NULL
4	NULL
,	NULL
France	NULL
Activated	NULL
T-lymphocytes	NULL
are	NULL
found	NULL
early	NULL
in	NULL
atherosclerosis	NULL
lesions	NULL
,	NULL
but	NULL
little	NULL
is	NULL
known	NULL
about	NULL
their	NULL
role	NULL
.	NULL

Oxidized	NULL
low-density	NULL
lipoproteins	NULL
(	NULL
OxLDLs	NULL
)	NULL
are	NULL
considered	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
the	NULL
lesions	NULL
,	NULL
and	NULL
we	NULL
have	NULL
previously	NULL
demonstrated	NULL
that	NULL
oxLDLs	NULL
inhibit	NULL
not	NULL
only	NULL
interleukin	NULL
(	NULL
IL	NULL
)	NULL
-2-receptor	NULL
expression	NULL
on	NULL
the	NULL
surface	NULL
of	NULL
in	NULL
vitro-activated	NULL
T-lymphocytes	NULL
but	NULL
also	NULL
their	NULL
proliferation	NULL
.	NULL

We	NULL
have	NULL
now	NULL
investigated	NULL
the	NULL
effect	NULL
of	NULL
oxLDLs	NULL
on	NULL
blast	NULL
differentiation	NULL
,	NULL
on	NULL
IL-2	NULL
synthesis	NULL
and	NULL
on	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
nuclear	NULL
factor	NULL
xB	NULL
(	NULL
NF-	NULL
«	NULL
B	NULL
)	NULL
system	NULL
in	NULL
activated	NULL
lymphocytes	NULL
.	NULL

Mildly	NULL
oxLDLs	NULL
(	NULL
50	NULL
and	NULL
100	NULL
ug/ml	NULL
)	NULL
decreased	NULL
the	NULL
number	NULL
of	NULL
lymphoblasts	NULL
and	NULL
the	NULL
level	NULL
of	NULL
IL-2	NULL
concentration	NULL
in	NULL
the	NULL
culture	NULL
supernatants	NULL
after	NULL
activation	NULL
of	NULL
lymphocytes	NULL
by	NULL
phytohaemagglutinin	NULL
and	NULL
PMA	NULL
+ionomycin	NULL
.	NULL

The	NULL
inhibition	NULL
of	NULL
IL-2	NULL
production	NULL
was	NULL
observed	NULL
in	NULL
the	NULL
CD3+*	NULL
T-lymphocyte	NULL
cytoplasm	NULL
as	NULL
early	NULL
as	NULL
4	NULL
h	NULL
after	NULL
activation	NULL
by	NULL
PMA	NULL
+ionomycin	NULL
.	NULL

The	NULL
study	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
showed	NULL
that	NULL
oxLDLs	NULL
led	NULL
to	NULL
a	NULL
decrease	NULL
of	NULL
activation-induced	NULL
p65/p50	NULL
NF-	NULL
«	NULL
B	NULL
heterodimer	NULL
binding	NULL
to	NULL
DNA	NULL
,	NULL
whereas	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
constitutive	NULL
nuclear	NULL
form	NULL
of	NULL
p50	NULL
dimer	NULL
was	NULL
unchanged	NULL
.	NULL

This	NULL
was	NULL
correlated	NULL
with	NULL
an	NULL
unchanged	NULL
level	NULL
of	NULL
the	NULL
active	NULL
form	NULL
of	NULL
the	NULL
cytosolic	NULL
inhibitor	NULL
protein	NULL
IxB-	NULL
«	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
observations	NULL
suggest	NULL
that	NULL
the	NULL
immunosuppressive	NULL
effect	NULL
of	NULL
oxLDLs	NULL
might	NULL
operate	NULL
via	NULL
a	NULL
dysregulation	NULL
of	NULL
the	NULL
T-lymphocyte	NULL
activation	NULL
mechanisms	NULL
.	NULL

Key	NULL
words	NULL
:	NULL
atherosclerosis	NULL
,	NULL
lipoproteins	NULL
,	NULL
lymphokines	NULL
,	NULL
IB	NULL
,	NULL
immunosuppression	NULL
INTRODUCTION	NULL
Low-density	NULL
lipoproteins	NULL
(	NULL
LDLs	NULL
)	NULL
deliver	NULL
cholesterol	NULL
and	NULL
other	NULL
lipids	NULL
to	NULL
peripheral	NULL
cells	NULL
[	NULL
1	NULL
]	NULL
.	NULL

Oxidized	NULL
LDLs	NULL
(	NULL
oOxLDLs	NULL
)	NULL
participate	NULL
in	NULL
the	NULL
development	NULL
of	NULL
atherosclerotic	NULL
lesions	NULL
[	NULL
2	NULL
]	NULL
.	NULL

Among	NULL
the	NULL
pleiotropic	NULL
effects	NULL
on	NULL
cellular	NULL
functions	NULL
,	NULL
oxLDLs	NULL
induce	NULL
the	NULL
production	NULL
of	NULL
interleukins	NULL
(	NULL
ILs	NULL
)	NULL
such	NULL
as	NULL
IL-1-	NULL
$	NULL
,	NULL
IL-8	NULL
,	NULL
IL-10	NULL
and	NULL
IL-1	NULL
2	NULL
in	NULL
resting	NULL
monocytes	NULL
[	NULL
3-5	NULL
]	NULL
and	NULL
inhibit	NULL
tumour	NULL
necrosis	NULL
factor	NULL
a	NULL
and	NULL
IL-1	NULL
#	NULL
mRNA	NULL
and	NULL
protein	NULL
expression	NULL
in	NULL
lipopolysaccharide-activated	NULL
macrophages	NULL
[	NULL
6	NULL
]	NULL
.	NULL

oxLDLs	NULL
may	NULL
also	NULL
activate	NULL
resting	NULL
lymphocytes	NULL
through	NULL
a	NULL
monocyte-mediated	NULL
process	NULL
[	NULL
4,7	NULL
]	NULL
,	NULL
but	NULL
they	NULL
inhibit	NULL
the	NULL
proliferation	NULL
of	NULL
activated	NULL
peripheral-blood	NULL
mononuclear	NULL
cells	NULL
(	NULL
PBMC	NULL
)	NULL
and	NULL
T	NULL
CD4*	NULL
lymphocytes	NULL
[	NULL
8,9	NULL
]	NULL
.	NULL

The	NULL
role	NULL
of	NULL
lymphocytes	NULL
in	NULL
atherosclerosis	NULL
has	NULL
not	NULL
been	NULL
clearly	NULL
defined	NULL
.	NULL

While	NULL
some	NULL
data	NULL
suggest	NULL
that	NULL
the	NULL
immune	NULL
system	NULL
plays	NULL
only	NULL
a	NULL
minor	NULL
role	NULL
in	NULL
atherogenesis	NULL
[	NULL
10,11	NULL
]	NULL
,	NULL
others	NULL
demonstrate	NULL
that	NULL
T-lymphocytes	NULL
participate	NULL
in	NULL
the	NULL
progression	NULL
of	NULL
the	NULL
lesions	NULL
[	NULL
12-15	NULL
]	NULL
.	NULL

For	NULL
example	NULL
,	NULL
atherosclerotic	NULL
lesions	NULL
are	NULL
reduced	NULL
in	NULL
T-cell-deficient	NULL
hyperlipidaemic	NULL
mice	NULL
[	NULL
12	NULL
]	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
some	NULL
authors	NULL
have	NULL
shown	NULL
that	NULL
lymphocytes	NULL
could	NULL
,	NULL
at	NULL
least	NULL
in	NULL
the	NULL
early	NULL
phase	NULL
,	NULL
slow	NULL
down	NULL
atherogenesis	NULL
[	NULL
16-20	NULL
]	NULL
,	NULL
e.g	NULL
.	NULL

the	NULL
B-lymphocyte	NULL
response	NULL
against	NULL
oxLDLs	NULL
has	NULL
a	NULL
protective	NULL
effect	NULL
against	NULL
lesion	NULL
development	NULL
in	NULL
rabbits	NULL
[	NULL
20	NULL
]	NULL
.	NULL

In	NULL
humans	NULL
,	NULL
activated	NULL
T-cells	NULL
are	NULL
present	NULL
early	NULL
in	NULL
atherosclerotic	NULL
lesions	NULL
[	NULL
21-23	NULL
]	NULL
.	NULL

The	NULL
mechanisms	NULL
involved	NULL
in	NULL
T-lymphocyte	NULL
activation	NULL
are	NULL
still	NULL
unknown	NULL
,	NULL
but	NULL
the	NULL
role	NULL
of	NULL
specific	NULL
antigens	NULL
such	NULL
as	NULL
OxLDLs	NULL
,	NULL
heat-shock	NULL
proteins	NULL
and	NULL
viral	NULL
proteins	NULL
has	NULL
been	NULL
suggested	NULL
[	NULL
7,22	NULL
]	NULL
.	NULL

Activation	NULL
of	NULL
T-cells	NULL
with	NULL
antigens	NULL
,	NULL
phorbol	NULL
esters	NULL
or	NULL
mitogens	NULL
can	NULL
trigger	NULL
a	NULL
programme	NULL
of	NULL
gene	NULL
expression	NULL
inducing	NULL
cell	NULL
proliferation	NULL
and	NULL
differentiation	NULL
.	NULL

Among	NULL
the	NULL
early	NULL
events	NULL
induced	NULL
after	NULL
activation	NULL
is	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
genes	NULL
for	NULL
IL-2	NULL
and	NULL
CD25	NULL
(	NULL
x-chain	NULL
of	NULL
IL-2	NULL
receptor	NULL
)	NULL
.	NULL

The	NULL
secretion	NULL
of	NULL
IL-2	NULL
and	NULL
the	NULL
expression	NULL
of	NULL
CD25	NULL
by	NULL
T-lymphocytes	NULL
are	NULL
necessary	NULL
for	NULL
their	NULL
lymphoblast	NULL
transformation	NULL
and	NULL
proliferation	NULL
.	NULL

Among	NULL
the	NULL
most	NULL
important	NULL
events	NULL
controlling	NULL
gene	NULL
activation	NULL
are	NULL
those	NULL
involving	NULL
the	NULL
nuclear	NULL
factor	NULL
«	NULL
B	NULL
(	NULL
NF-	NULL
«	NULL
B	NULL
)	NULL
family	NULL
[	NULL
24,25	NULL
]	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
is	NULL
present	NULL
in	NULL
an	NULL
inactive	NULL
form	NULL
in	NULL
the	NULL
cytoplasm	NULL
of	NULL
resting	NULL
T-cells	NULL
,	NULL
bound	NULL
to	NULL
the	NULL
inhibitor	NULL
proteins	NULL
termed	NULL
IB	NULL
(	NULL
inhibitor	NULL
of	NULL
«	NULL
B	NULL
)	NULL
.	NULL

A	NULL
member	NULL
of	NULL
this	NULL
family	NULL
,	NULL
IxB-	NULL
«	NULL
,	NULL
binds	NULL
the	NULL
p50/p65	NULL
heterodimer	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
the	NULL
cytoplasm	NULL
.	NULL

After	NULL
activation	NULL
[	NULL
e.g	NULL
.	NULL

by	NULL
phytohaemagglutinin	NULL
(	NULL
PHA	NULL
)	NULL
or	NULL
PMA	NULL
+ionomycin	NULL
]	NULL
,	NULL
IxB-	NULL
«	NULL
is	NULL
phosphorylated	NULL
,	NULL
ubiqui-tinated	NULL
and	NULL
degraded	NULL
,	NULL
whereas	NULL
the	NULL
p50/p65	NULL
heterodimer	NULL
trans-locates	NULL
into	NULL
the	NULL
nucleus	NULL
,	NULL
specifically	NULL
binds	NULL
the	NULL
DNA-	NULL
«	NULL
B	NULL
region	NULL
and	NULL
activates	NULL
gene	NULL
transcription	NULL
[	NULL
24,26	NULL
]	NULL
.	NULL

Functional	NULL
«	NULL
B	NULL
elements	NULL
have	NULL
been	NULL
found	NULL
on	NULL
the	NULL
promoters	NULL
of	NULL
the	NULL
IL-2	NULL
and	NULL
CD25	NULL
genes	NULL
[	NULL
24	NULL
]	NULL
.	NULL

In	NULL
a	NULL
recent	NULL
work	NULL
we	NULL
have	NULL
demonstrated	NULL
that	NULL
mildly	NULL
oxLDLs	NULL
suppress	NULL
the	NULL
T-lymphocyte	NULL
proliferative	NULL
response	NULL
.	NULL

This	NULL
observation	NULL
suggests	NULL
that	NULL
oOxLDLs	NULL
may	NULL
inhibit	NULL
T-cell	NULL
responses	NULL
in	NULL
atheroslerotic	NULL
lesions	NULL
[	NULL
9	NULL
]	NULL
.	NULL

Mildly	NULL
oxLDLs	NULL
were	NULL
obtained	NULL
using	NULL
UV	NULL
radiation	NULL
and	NULL
were	NULL
characterized	NULL
by	NULL
relatively	NULL
low	NULL
levels	NULL
of	NULL
peroxidation	NULL
products	NULL
without	NULL
major	NULL
apolipoprotein	NULL
B	NULL
(	NULL
apoB	NULL
)	NULL
alteration	NULL
,	NULL
which	NULL
permitted	NULL
uptake	NULL
of	NULL
oxLDLs	NULL
through	NULL
the	NULL
normal	NULL
apoB/E-receptor	NULL
pathway	NULL
[	NULL
27	NULL
]	NULL
.	NULL

In	NULL
the	NULL
present	NULL
work	NULL
we	NULL
have	NULL
studied	NULL
the	NULL
effect	NULL
of	NULL
oxLDLs	NULL
on	NULL
NF-KB	NULL
activation	NULL
and	NULL
IL-2	NULL
synthesis	NULL
,	NULL
which	NULL
are	NULL
early	NULL
events	NULL
induced	NULL
by	NULL
activation	NULL
of	NULL
T-lymphocytes	NULL
.	NULL

Abbreviations	NULL
used	NULL
:	NULL
LDL	NULL
,	NULL
low-density	NULL
lipoprotein	NULL
;	NULL
oxidized	NULL
LDL	NULL
,	NULL
oxLDL	NULL
;	NULL
apoB	NULL
,	NULL
apolipoprotein	NULL
B	NULL
;	NULL
PBMC	NULL
,	NULL
peripheral-blood	NULL
mononuclear	NULL
cell	NULL
;	NULL
PBL	NULL
,	NULL
peripheral-blood	NULL
lymphocytes	NULL
;	NULL
IL	NULL
,	NULL
interleukin	NULL
;	NULL
LPDS	NULL
,	NULL
lipoprotein-depleted	NULL
serum	NULL
;	NULL
TBARS	NULL
,	NULL
thiobarbituric	NULL
acid-reactive	NULL
substances	NULL
;	NULL
FCS	NULL
,	NULL
fetal-calf	NULL
serum	NULL
;	NULL
PHA	NULL
,	NULL
phytohaemagglutinin	NULL
;	NULL
EMSA	NULL
,	NULL
electrophoretic-mobility-shift	NULL
assay	NULL
;	NULL
LPS	NULL
,	NULL
lipopolysaccharide	NULL
.	NULL

!	NULL

To	NULL
whom	NULL
correspondence	NULL
should	NULL
be	NULL
addressed	NULL
(	NULL
e-mail	NULL
hbenoist	NULL
@	NULL
rangueil.inserm.fr	NULL
)	NULL
.	NULL

270	NULL
S.	NULL
Caspar-Bauguil	NULL
and	NULL
others	NULL
MATERIALS	NULL
AND	NULL
METHODS	NULL
Materials	NULL
Nonidet	NULL
P40	NULL
(	NULL
Igepal	NULL
)	NULL
,	NULL
phytohaemagglutinin-protein	NULL
,	NULL
PMA	NULL
,	NULL
ionomycin	NULL
,	NULL
PMSF	NULL
,	NULL
leupeptin	NULL
,	NULL
aprotinin	NULL
,	NULL
pepstatin	NULL
,	NULL
BSA	NULL
,	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
and	NULL
saponin	NULL
were	NULL
supplied	NULL
from	NULL
Sigma	NULL
(	NULL
Sigma-Merck	NULL
,	NULL
Darm-stadt	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

RPMI	NULL
1640	NULL
medium	NULL
containing	NULL
Glutamax	NULL
I	NULL
,	NULL
penicillin	NULL
,	NULL
streptomycin	NULL
,	NULL
sodium	NULL
pyruvate	NULL
were	NULL
purchased	NULL
from	NULL
Gibco	NULL
(	NULL
Cergy-Pontoise	NULL
,	NULL
France	NULL
)	NULL
.	NULL

T	NULL
,	NULL
polynucleotide	NULL
kinase	NULL
,	NULL
NF-	NULL
«	NULL
B	NULL
site	NULL
of	NULL
the	NULL
«	NULL
-light-chain	NULL
enhancer	NULL
(	NULL
5-AGTTGAGGGGAC-TTTCCCAGGC-3	NULL
'	NULL
)	NULL
and	NULL
API	NULL
site	NULL
(	NULL
5-CGCTTGATGAGTCA-GCCGGAA-3	NULL
'	NULL
)	NULL
were	NULL
provided	NULL
by	NULL
Promega	NULL
(	NULL
Madison	NULL
,	NULL
WI	NULL
,	NULL
U.S.A.	NULL
)	NULL
.	NULL

[	NULL
y-*°P	NULL
]	NULL
ATP	NULL
and	NULL
[	NULL
*H	NULL
]	NULL
thymidine	NULL
were	NULL
from	NULL
ICN	NULL
(	NULL
Orsay	NULL
,	NULL
France	NULL
)	NULL
.	NULL

Acrylamide	NULL
stock	NULL
solution	NULL
(	NULL
40	NULL
%	NULL
)	NULL
and	NULL
lymphocyte	NULL
separation	NULL
medium	NULL
were	NULL
obtained	NULL
from	NULL
Eurobio	NULL
(	NULL
Les	NULL
Ulis	NULL
,	NULL
France	NULL
)	NULL
.	NULL

LDL	NULL
isolation	NULL
and	NULL
oxidation	NULL
LDLs	NULL
(	NULL
d=	NULL
1.019-1.063	NULL
)	NULL
and	NULL
lipoprotein-depleted	NULL
serum	NULL
(	NULL
LPDS	NULL
)	NULL
were	NULL
isolated	NULL
from	NULL
pooled	NULL
fresh	NULL
human	NULL
sera	NULL
,	NULL
dialysed	NULL
,	NULL
sterilized	NULL
and	NULL
stored	NULL
at	NULL
4	NULL
°C	NULL
as	NULL
previously	NULL
described	NULL
[	NULL
27	NULL
]	NULL
.	NULL

Mildly	NULL
oxLDLs	NULL
(	NULL
containing	NULL
mainly	NULL
lipid	NULL
peroxidation	NULL
derivatives	NULL
with	NULL
only	NULL
minor	NULL
alterations	NULL
of	NULL
apoB	NULL
)	NULL
obtained	NULL
by	NULL
irradiation	NULL
by	NULL
UV	NULL
light	NULL
(	NULL
UV-C	NULL
,	NULL
254	NULL
nm	NULL
,	NULL
0.5	NULL
mW	NULL
/em*	NULL
,	NULL
for	NULL
2	NULL
h	NULL
)	NULL
[	NULL
27	NULL
]	NULL
were	NULL
used	NULL
.	NULL

LDLs	NULL
contained	NULL
0.2	NULL
+0.1	NULL
nmol	NULL
of	NULL
thiobarbituric	NULL
acid-reactive	NULL
substances	NULL
(	NULL
TBARS	NULL
)	NULL
/mg	NULL
of	NULL
apoB	NULL
and	NULL
15+3	NULL
nmol	NULL
of	NULL
hydroperoxides/mg	NULL
of	NULL
apoB	NULL
and	NULL
oxLDLs	NULL
contained	NULL
44+	NULL
0.4	NULL
nmol	NULL
TBARS	NULL
$	NULL
S/mg	NULL
apoB	NULL
and	NULL
92	NULL
+11	NULL
nmol	NULL
mg	NULL
apoB	NULL
.	NULL

In	NULL
some	NULL
experiments	NULL
LDLs	NULL
were	NULL
oxidized	NULL
by	NULL
CuSO	NULL
,	NULL
(	NULL
5	NULL
aM	NULL
,	NULL
2	NULL
h	NULL
,	NULL
37	NULL
°C	NULL
)	NULL
and	NULL
contained	NULL
3.8	NULL
+0.8	NULL
nmol	NULL
of	NULL
TBARS/mg	NULL
of	NULL
apoB	NULL
and	NULL
154	NULL
+13	NULL
nmol	NULL
of	NULL
hydroperoxides	NULL
of	NULL
apoB	NULL
under	NULL
our	NULL
experimental	NULL
conditions	NULL
.	NULL

Cell	NULL
culture	NULL
and	NULL
activation	NULL
of	NULL
lymphocytes	NULL
PBMC	NULL
were	NULL
separated	NULL
from	NULL
heparinized	NULL
venous	NULL
blood	NULL
of	NULL
five	NULL
healthy	NULL
donors	NULL
by	NULL
centrifugation	NULL
(	NULL
20	NULL
min	NULL
,	NULL
1500	NULL
g	NULL
)	NULL
,	NULL
using	NULL
a	NULL
lymphocyte	NULL
separation	NULL
medium	NULL
.	NULL

Peripheral-blood	NULL
lymphocytes	NULL
(	NULL
PBL	NULL
)	NULL
were	NULL
obtained	NULL
by	NULL
removing	NULL
adherent	NULL
cells	NULL
after	NULL
PBMC	NULL
incubation	NULL
(	NULL
2	NULL
h	NULL
,	NULL
37	NULL
°C	NULL
)	NULL
in	NULL
60-mm-diameter	NULL
plastic	NULL
Petri	NULL
dishes	NULL
.	NULL

The	NULL
PBL	NULL
suspensions	NULL
contained	NULL
approx	NULL
.	NULL

75-85	NULL
%	NULL
T-cells	NULL
,	NULL
5-10	NULL
%	NULL
B-cells	NULL
,	NULL
10-15	NULL
%	NULL
Natural	NULL
Killer	NULL
cells	NULL
and	NULL
0.5-1	NULL
%	NULL
monocytes	NULL
.	NULL

During	NULL
experiments	NULL
,	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
containing	NULL
Glutamax	NULL
I	NULL
,	NULL
supplemented	NULL
with	NULL
penicillin	NULL
(	NULL
100	NULL
units/	NULL
ml	NULL
)	NULL
,	NULL
streptomycin	NULL
(	NULL
100	NULL
ug/ml	NULL
)	NULL
,	NULL
sodium	NULL
pyruvate	NULL
(	NULL
1	NULL
mM	NULL
)	NULL
and	NULL
2	NULL
%	NULL
LPDS	NULL
.	NULL

Cells	NULL
were	NULL
activated	NULL
by	NULL
PHA	NULL
(	NULL
1	NULL
ug/ml	NULL
!	NULL
)	NULL

or	NULL
PMA	NULL
(	NULL
10	NULL
ng/ml	NULL
!	NULL
)	NULL

and	NULL
ionomycin	NULL
(	NULL
100	NULL
ng/ml	NULL
)	NULL
.	NULL

PHA	NULL
is	NULL
known	NULL
to	NULL
activate	NULL
only	NULL
some	NULL
T-cell	NULL
subpopulations	NULL
in	NULL
PBL	NULL
(	NULL
mimicking	NULL
the	NULL
effect	NULL
of	NULL
antigens	NULL
that	NULL
activate	NULL
T-cells	NULL
through	NULL
T-cell	NULL
receptor	NULL
signalling	NULL
)	NULL
[	NULL
24,28-31	NULL
]	NULL
,	NULL
whereas	NULL
PMA	NULL
+ionomycin	NULL
can	NULL
potentially	NULL
activate	NULL
all	NULL
lymphocyte	NULL
populations	NULL
[	NULL
24,28	NULL
]	NULL
.	NULL

Previous	NULL
pharmacological	NULL
studies	NULL
showed	NULL
that	NULL
the	NULL
activator	NULL
concentrations	NULL
used	NULL
are	NULL
sufficient	NULL
to	NULL
promote	NULL
T-cell	NULL
stimulation	NULL
,	NULL
including	NULL
the	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
the	NULL
production	NULL
of	NULL
IL-2	NULL
and	NULL
CD25	NULL
and	NULL
cell	NULL
proliferation	NULL
[	NULL
28	NULL
]	NULL
.	NULL

Proliferative	NULL
assays	NULL
and	NULL
cell-viability	NULL
evaluation	NULL
Proliferation	NULL
was	NULL
measured	NULL
by	NULL
the	NULL
standard	NULL
uptake	NULL
assay	NULL
as	NULL
follows	NULL
.	NULL

Cells	NULL
(	NULL
10	NULL
%	NULL
/ml	NULL
of	NULL
RPMI/2	NULL
%	NULL
LPDS	NULL
)	NULL
were	NULL
seeded	NULL
in	NULL
round-bottomed	NULL
96-well	NULL
plates	NULL
(	NULL
100	NULL
wl/well	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
incubated	NULL
from	NULL
24	NULL
to	NULL
72	NULL
h	NULL
at	NULL
37	NULL
°C	NULL
in	NULL
a	NULL
humidified	NULL
atmosphere	NULL
with	NULL
5	NULL
%	NULL
CO	NULL
,	NULL
.	NULL

A	NULL
1	NULL
4Ci	NULL
portion	NULL
of	NULL
[	NULL
H	NULL
]	NULL
thymidine	NULL
(	NULL
1	NULL
Ci	NULL
=	NULL
37	NULL
Gbq	NULL
;	NULL
ICN	NULL
,	NULL
Orsay	NULL
,	NULL
France	NULL
)	NULL
was	NULL
added	NULL
to	NULL
each	NULL
well	NULL
for	NULL
the	NULL
last	NULL
16	NULL
h.	NULL
Cells	NULL
were	NULL
harvested	NULL
on	NULL
glass-fibre	NULL
filters	NULL
by	NULL
means	NULL
of	NULL
a	NULL
semi-automatic	NULL
cell	NULL
harvester	NULL
(	NULL
Harvester	NULL
96°	NULL
Tomtec	NULL
;	NULL
Wallac-EG	NULL
&	NULL
G	NULL
Instruments	NULL
,	NULL
Evry	NULL
,	NULL
France	NULL
)	NULL
,	NULL
and	NULL
the	NULL
amount	NULL
of	NULL
{	NULL
H	NULL
]	NULL
thymidine	NULL
(	NULL
c.p.m	NULL
.	NULL
)	NULL

incorporated	NULL
was	NULL
determined	NULL
on	NULL
Micro-beta®	NULL
trilux	NULL
(	NULL
Wallac-EG	NULL
&	NULL
G	NULL
instruments	NULL
)	NULL
.	NULL

The	NULL
mean	NULL
radioactivity	NULL
from	NULL
triplicate	NULL
cultures	NULL
was	NULL
used	NULL
for	NULL
calculation	NULL
.	NULL

In	NULL
some	NULL
experiments	NULL
,	NULL
recombinant	NULL
IL-2	NULL
(	NULL
generously	NULL
given	NULL
by	NULL
SANOFI	NULL
,	NULL
Labége	NULL
,	NULL
France	NULL
)	NULL
was	NULL
added	NULL
.	NULL

The	NULL
cell	NULL
viability	NULL
was	NULL
determined	NULL
by	NULL
the	NULL
Trypan	NULL
Blue-exclusion	NULL
test	NULL
and	NULL
detection	NULL
of	NULL
apo2.7	NULL
antigen	NULL
by	NULL
flow-cytofluorimetric	NULL
analysis	NULL
.	NULL

Flow-cytofluorimetric	NULL
analysis	NULL
PBL	NULL
were	NULL
surface-labelled	NULL
with	NULL
phycoerythrin-conjugated	NULL
anti-CD3	NULL
(	NULL
IOT	NULL
,	NULL
Marseille	NULL
,	NULL
France	NULL
)	NULL
and	NULL
Tri	NULL
Color-conjugated	NULL
anti-CD25	NULL
antibodies	NULL
(	NULL
Tebu	NULL
,	NULL
Le	NULL
Perray	NULL
en	NULL
Yvelines	NULL
,	NULL
France	NULL
)	NULL
.	NULL

Lymphocyte	NULL
and	NULL
lymphoblast	NULL
events	NULL
were	NULL
gated	NULL
on	NULL
the	NULL
side	NULL
scatter	NULL
(	NULL
granularity	NULL
)	NULL
and	NULL
forward	NULL
scatter	NULL
(	NULL
size	NULL
)	NULL
dot-plot	NULL
and	NULL
selected	NULL
cells	NULL
were	NULL
then	NULL
analysed	NULL
by	NULL
double	NULL
fluorescence	NULL
.	NULL

Intracytoplasmic	NULL
cytokine	NULL
(	NULL
IL-2	NULL
)	NULL
detection	NULL
was	NULL
performed	NULL
according	NULL
to	NULL
a	NULL
method	NULL
used	NULL
for	NULL
the	NULL
examination	NULL
of	NULL
cytokine	NULL
kinetics	NULL
in	NULL
Th1/Th2	NULL
balance	NULL
(	NULL
L.	NULL
Rostaing	NULL
,	NULL
J.	NULL
Tkaczuk	NULL
and	NULL
M.	NULL
Durand	NULL
,	NULL
unpublished	NULL
work	NULL
;	NULL
full	NULL
details	NULL
are	NULL
available	NULL
from	NULL
M.D	NULL
.	NULL

on	NULL
request	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
after	NULL
0.3	NULL
%	NULL
formaldehyde	NULL
/PBS	NULL
fixation	NULL
,	NULL
cells	NULL
were	NULL
first	NULL
labelled	NULL
at	NULL
the	NULL
surface	NULL
with	NULL
a	NULL
peridinin-chlorophyll-protein-conjugated	NULL
anti-CD3	NULL
antibody	NULL
(	NULL
Becton-Dickinson	NULL
,	NULL
Le	NULL
Pont	NULL
de	NULL
Claix	NULL
,	NULL
France	NULL
)	NULL
and	NULL
then	NULL
perforated	NULL
with	NULL
0.1	NULL
%	NULL
saponin/	NULL
PBS	NULL
.	NULL

An	NULL
appropriate	NULL
dilution	NULL
of	NULL
a	NULL
phycoerythrin-conjugated	NULL
anti-IL-2	NULL
antibody	NULL
(	NULL
Becton-Dickinson	NULL
)	NULL
was	NULL
then	NULL
added	NULL
for	NULL
a	NULL
30	NULL
min	NULL
incubation	NULL
.	NULL

After	NULL
washing	NULL
,	NULL
cells	NULL
were	NULL
fixed	NULL
in	NULL
0.5	NULL
%	NULL
formaldehyde/PBS	NULL
before	NULL
cytofluorimetric	NULL
acquisition	NULL
.	NULL

Preparation	NULL
of	NULL
cell	NULL
extracts	NULL
PBL	NULL
were	NULL
harvested	NULL
and	NULL
washed	NULL
twice	NULL
in	NULL
cold	NULL
PBS	NULL
,	NULL
resuspended	NULL
in	NULL
0.4	NULL
ml	NULL
(	NULL
per	NULL
10°	NULL
cells	NULL
)	NULL
of	NULL
buffer	NULL
A	NULL
(	NULL
10	NULL
mM	NULL
Hepes/10	NULL
mM	NULL
KCl/1	NULL
mM	NULL
-	NULL
MgCl	NULL
,	NULL
/l1	NULL
mM	NULL
-	NULL
dithiothreitol/0.1	NULL
mM	NULL
-	NULL
EGTA/	NULL
0.5	NULL
mM	NULL
EDTA/lmM	NULL
PMSF/2	NULL
ug/ml	NULL
leupeptin/10	NULL
ug/ml	NULL
aprotinin/2	NULL
ug/ml	NULL
pepstatin	NULL
)	NULL
,	NULL
and	NULL
incubated	NULL
on	NULL
ice	NULL
for	NULL
20	NULL
min	NULL
.	NULL

A	NULL
25	NULL
ul	NULL
portion	NULL
of	NULL
10	NULL
%	NULL
Nonidet	NULL
P40	NULL
was	NULL
next	NULL
added	NULL
,	NULL
cells	NULL
were	NULL
mixed	NULL
vigorously	NULL
for	NULL
10s	NULL
and	NULL
centrifuged	NULL
(	NULL
1200	NULL
g	NULL
,	NULL
20	NULL
min	NULL
)	NULL
.	NULL

Supernatants	NULL
corresponding	NULL
to	NULL
the	NULL
cytosolic	NULL
fraction	NULL
were	NULL
used	NULL
directly	NULL
for	NULL
immunoblotting	NULL
.	NULL

Pelleted	NULL
nuclei	NULL
were	NULL
washed	NULL
once	NULL
with	NULL
buffer	NULL
A	NULL
,	NULL
resuspended	NULL
in	NULL
40	NULL
l	NULL
of	NULL
buffer	NULL
C	NULL
(	NULL
20	NULL
mM	NULL
Hepes/	NULL
400	NULL
mM	NULL
NaCl/1	NULL
mM	NULL
MgCl	NULL
,	NULL
/l1	NULL
mM	NULL
dithiothreitol/0.1	NULL
mM	NULL
EGTA/O.5	NULL
mM	NULL
EDTA/lmM	NULL
_	NULL
PMSF/2ug/ml	NULL
-	NULL
leupeptin/	NULL
10	NULL
ug/ml	NULL
aprotinin/2	NULL
ug/ml	NULL
pepstatin	NULL
)	NULL
,	NULL
incubated	NULL
on	NULL
ice	NULL
for	NULL
30	NULL
min	NULL
and	NULL
centrifuged	NULL
(	NULL
20000g	NULL
,	NULL
20	NULL
mn	NULL
)	NULL
.	NULL

The	NULL
supernatants	NULL
containing	NULL
the	NULL
nuclear	NULL
proteins	NULL
were	NULL
used	NULL
for	NULL
electrophoretic-mobility-shift	NULL
assay	NULL
(	NULL
EMSA	NULL
)	NULL
analyses	NULL
.	NULL

Protein	NULL
concentration	NULL
was	NULL
measured	NULL
with	NULL
a	NULL
commercial	NULL
kit	NULL
(	NULL
Bio-Rad	NULL
protein	NULL
assay	NULL
,	NULL
Bio-Rad	NULL
Laboratories	NULL
,	NULL
Miinchen	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

Immunoblotting	NULL
analysis	NULL
After	NULL
heating	NULL
,	NULL
60	NULL
ug	NULL
of	NULL
cell	NULL
protein	NULL
was	NULL
resolved	NULL
by	NULL
SDS/PAGE	NULL
on	NULL
10	NULL
%	NULL
-acrylamide	NULL
gels	NULL
and	NULL
transferred	NULL
on	NULL
to	NULL
nitrocellulose	NULL
membrane	NULL
(	NULL
Hybond-C	NULL
;	NULL
Amersham	NULL
International	NULL
,	NULL
Amersham	NULL
,	NULL
Bucks	NULL
.	NULL

,	NULL
U.K.	NULL
)	NULL
.	NULL

The	NULL
specific	NULL
antigens	NULL
were	NULL
detected	NULL
with	NULL
anti-IkxB-	NULL
«	NULL
and	NULL
actin	NULL
antibodies	NULL
(	NULL
Tebu	NULL
)	NULL
and	NULL
revealed	NULL
by	NULL
the	NULL
Amersham	NULL
enhanced-chemiluminiscence	NULL
(	NULL
ECL®	NULL
)	NULL
method	NULL
.	NULL

EMSA	NULL
The	NULL
double-strand	NULL
NF-	NULL
«	NULL
B	NULL
oligonucleotide	NULL
was	NULL
end-la	NULL
belled	NULL
using	NULL
[	NULL
y-**P	NULL
]	NULL
JATP	NULL
and	NULL
T	NULL
,	NULL
polynucleotide	NULL
kinase	NULL
and	NULL
purified	NULL
on	NULL
a	NULL
commercial	NULL
column	NULL
(	NULL
Qiaquick	NULL
;	NULL
Qiagen	NULL
,	NULL
Hilden	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

Reactions	NULL
with	NULL
equal	NULL
amounts	NULL
of	NULL
nuclear	NULL
extracts	NULL
(	NULL
2.5	NULL
ug/reaction	NULL
)	NULL
T-lymphocyte	NULL
activation	NULL
and	NULL
oxidized	NULL
low-density	NULL
lipoproteins	NULL
271	NULL
were	NULL
carried	NULL
out	NULL
in	NULL
20	NULL
zl	NULL
of	NULL
buffer	NULL
[	NULL
2	NULL
mM	NULL
Hepes/50	NULL
mM	NULL
100	NULL
12500	NULL
NaCl/1	NULL
mM	NULL
MgCl	NULL
,	NULL
/2.5	NULL
mM	NULL
dithiothreitol/0.5	NULL
mM	NULL
EDTA/4	NULL
%	NULL
o	NULL
B	NULL
glycerol/200	NULL
ug/ml	NULL
BSA/6	NULL
ug/ml	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
containing	NULL
a	NULL
€	NULL
*	NULL
k	NULL
&	NULL
so-probe	NULL
with	NULL
100000	NULL
c.p.m	NULL
.	NULL

,	NULL
for	NULL
30	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

&	NULL
so	NULL
|	NULL
759	NULL
%	NULL
E	NULL
Samples	NULL
were	NULL
loaded	NULL
on	NULL
a	NULL
native	NULL
6	NULL
%	NULL
-polyacrylamide	NULL
gel	NULL
con-	NULL
%	NULL
|-	NULL
sooo	NULL
E	NULL
%	NULL
*	NULL
taining	NULL
0.5	NULL
x	NULL
TBE	NULL
(	NULL
50	NULL
mM	NULL
of	NULL
Tris/borate/2	NULL
mM	NULL
EDTA	NULL
,	NULL
pH	NULL
8	NULL
)	NULL
.	NULL

©	NULL
se	NULL
)	NULL
-	NULL
2500	NULL
3	NULL
*	NULL
so-After	NULL
electrophoresis	NULL
,	NULL
dried	NULL
gels	NULL
were	NULL
exposed	NULL
at	NULL
-80	NULL
°C	NULL
.	NULL

Competition	NULL
assays	NULL
were	NULL
carried	NULL
out	NULL
with	NULL
1	NULL
mg	NULL
of	NULL
specific	NULL
anti-p50	NULL
or	NULL
°	NULL
°	NULL
ar	NULL
ar	NULL
oe	NULL
anti-p65	NULL
antibodies	NULL
(	NULL
Tebu	NULL
)	NULL
and	NULL
a	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
Time	NULL
(	NULL
h	NULL
)	NULL
unlabelled	NULL
oligonucleotides	NULL
.	NULL

Enzyme	NULL
immunoassay	NULL
é	NULL
159	NULL
Cells	NULL
were	NULL
activated	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Extracellular	NULL
secreted	NULL
eca	NULL
IL-2	NULL
was	NULL
detected	NULL
with	NULL
a	NULL
commercial	NULL
kit	NULL
(	NULL
Immunotech	NULL
,	NULL
Marseille	NULL
)	NULL
05,2	NULL
e_	NULL
according	NULL
to	NULL
the	NULL
supplier	NULL
's	NULL
recommendations	NULL
.	NULL

é	NULL
;	NULL
so	NULL
4	NULL
(	NULL
hell	NULL
,	NULL
RESULTS	NULL
CoA	NULL
z	NULL
h	NULL
.	NULL

.	NULL

apo	NULL
B	NULL
(	NULL
g/m	NULL
!	NULL
)	NULL

apoB	NULL
(	NULL
g/m	NULL
!	NULL
)	NULL

Effect	NULL
of	NULL
oxLDLs	NULL
on	NULL
DNA	NULL
synthesis	NULL
and	NULL
lymphoblast	NULL
recruitment	NULL
after	NULL
PHA	NULL
activation	NULL
of	NULL
PBL	NULL
Figure	NULL
1	NULL
-	NULL
Effect	NULL
of	NULL
oxLDLs	NULL
on	NULL
the	NULL
blast	NULL
transformation	NULL
and	NULL
the	NULL
proliferation	NULL
The	NULL
majority	NULL
of	NULL
lymphocytes	NULL
in	NULL
the	NULL
blood	NULL
are	NULL
in	NULL
resting	NULL
state	NULL
(	NULL
G	NULL
,	NULL
-phase	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
lymphocytes	NULL
induces	NULL
their	NULL
transformation	NULL
to	NULL
lymphoblasts	NULL
and	NULL
the	NULL
commitment	NULL
to	NULL
the	NULL
cell	NULL
cycle	NULL
[	NULL
29	NULL
]	NULL
.	NULL

The	NULL
lymphoblast	NULL
population	NULL
can	NULL
be	NULL
discriminated	NULL
from	NULL
resting	NULL
lymphocytes	NULL
by	NULL
a	NULL
cytofluorimetric	NULL
analysis	NULL
using	NULL
side-scatter	NULL
(	NULL
granularity	NULL
)	NULL
and	NULL
forward-scatter	NULL
(	NULL
size	NULL
)	NULL
parameters	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
demonstrated	NULL
that	NULL
mildly	NULL
oxLDLs	NULL
(	NULL
over	NULL
10	NULL
ug/ml	NULL
!	NULL
)	NULL

inhibited	NULL
the	NULL
{	NULL
H	NULL
]	NULL
thymidine	NULL
uptake	NULL
by	NULL
activated	NULL
T-lymphocytes	NULL
without	NULL
cell-death	NULL
increase	NULL
[	NULL
9	NULL
]	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Figure	NULL
1	NULL
(	NULL
A	NULL
)	NULL
,	NULL
the	NULL
inhibition	NULL
is	NULL
correlated	NULL
with	NULL
a	NULL
decrease	NULL
in	NULL
the	NULL
blast	NULL
population	NULL
.	NULL

This	NULL
effect	NULL
was	NULL
time-	NULL
and	NULL
concentration-dependent	NULL
(	NULL
Figures	NULL
1A	NULL
and	NULL
1B	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
the	NULL
mitogenic	NULL
response	NULL
to	NULL
PHA	NULL
of	NULL
PBL	NULL
preincubated	NULL
for	NULL
24	NULL
h	NULL
with	NULL
oxLDLs	NULL
(	NULL
10	NULL
,	NULL
50	NULL
and	NULL
100	NULL
ug/ml	NULL
)	NULL
and	NULL
then	NULL
washed	NULL
was	NULL
not	NULL
inhibited	NULL
and	NULL
was	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
cells	NULL
preincubated	NULL
with	NULL
native	NULL
LDLs	NULL
,	NULL
suggesting	NULL
that	NULL
oxLDLs	NULL
are	NULL
not	NULL
toxic	NULL
on	NULL
resting	NULL
lymphocytes	NULL
after	NULL
24	NULL
h	NULL
incubation	NULL
.	NULL

The	NULL
preincubation	NULL
with	NULL
oxLDLs	NULL
did	NULL
not	NULL
decrease	NULL
the	NULL
sensitivity	NULL
of	NULL
lymphocytes	NULL
to	NULL
PHA	NULL
stimulation	NULL
(	NULL
Figure	NULL
1C	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
experiments	NULL
indicated	NULL
that	NULL
a	NULL
co-incubation	NULL
for	NULL
24	NULL
h	NULL
of	NULL
PBL	NULL
with	NULL
PHA	NULL
+	NULL
oxLDLs	NULL
is	NULL
sufficient	NULL
to	NULL
induce	NULL
an	NULL
inhibitory	NULL
effect	NULL
on	NULL
cell	NULL
proliferation	NULL
(	NULL
Figure	NULL
1D	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
oxLDLs	NULL
can	NULL
alter	NULL
the	NULL
events	NULL
triggering	NULL
the	NULL
DNA	NULL
synthesis	NULL
in	NULL
activated	NULL
T-lymphocytes	NULL
during	NULL
the	NULL
first	NULL
24	NULL
h.	NULL
Among	NULL
the	NULL
first	NULL
steps	NULL
of	NULL
activation	NULL
is	NULL
the	NULL
binding	NULL
of	NULL
PHA	NULL
to	NULL
the	NULL
cell	NULL
surface	NULL
of	NULL
T-lymphocytes	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
demonstrated	NULL
that	NULL
the	NULL
inhibition	NULL
is	NULL
not	NULL
due	NULL
to	NULL
interference	NULL
of	NULL
oxLDLs	NULL
with	NULL
the	NULL
binding	NULL
of	NULL
PHA	NULL
[	NULL
9	NULL
]	NULL
.	NULL

Effect	NULL
of	NULL
oxLDLs	NULL
on	NULL
IL-2	NULL
secretion	NULL
of	NULL
T-lymphocytes	NULL
As	NULL
shown	NULL
in	NULL
Figure	NULL
2A	NULL
,	NULL
when	NULL
lymphocytes	NULL
were	NULL
activated	NULL
by	NULL
PHA	NULL
the	NULL
IL-2	NULL
concentration	NULL
rose	NULL
sharply	NULL
during	NULL
the	NULL
first	NULL
24	NULL
h	NULL
and	NULL
decreased	NULL
afterwards	NULL
in	NULL
supernatants	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
native	NULL
LDLs	NULL
(	NULL
100	NULL
and	NULL
200	NULL
ug/ml	NULL
)	NULL
maintained	NULL
(	NULL
or	NULL
increased	NULL
)	NULL
the	NULL
IL-2	NULL
level	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
incubation	NULL
with	NULL
oxLDLs	NULL
(	NULL
100	NULL
or	NULL
200	NULL
ug/ml	NULL
)	NULL
induced	NULL
a	NULL
significant	NULL
decrease	NULL
of	NULL
IL-2	NULL
concentration	NULL
as	NULL
soon	NULL
as	NULL
24h	NULL
after	NULL
activation	NULL
.	NULL

Moreover	NULL
,	NULL
this	NULL
inhibition	NULL
was	NULL
directly	NULL
correlated	NULL
with	NULL
the	NULL
TBARS	NULL
and	NULL
hydroperoxide	NULL
levels	NULL
of	NULL
oxLDLs	NULL
(	NULL
results	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
comparison	NULL
of	NULL
UV-oxLDLs	NULL
with	NULL
2	NULL
h-Cu-oxLDLs	NULL
,	NULL
characterized	NULL
by	NULL
a	NULL
similar	NULL
mild	NULL
oxidization	NULL
level	NULL
,	NULL
indicated	NULL
that	NULL
the	NULL
inhibition	NULL
of	NULL
IL-2	NULL
secretion	NULL
(	NULL
Figure	NULL
2B	NULL
)	NULL
or	NULL
of	NULL
PHA-induced	NULL
proliferation	NULL
(	NULL
results	NULL
not	NULL
shown	NULL
)	NULL
was	NULL
independent	NULL
of	NULL
the	NULL
oxidation	NULL
methods	NULL
.	NULL

For	NULL
examining	NULL
the	NULL
earlier	NULL
effect	NULL
of	NULL
oxLDLs	NULL
,	NULL
the	NULL
intracytoplasmic	NULL
IL-2	NULL
level	NULL
was	NULL
analysed	NULL
by	NULL
cytofluorimetry	NULL
.	NULL

In	NULL
PHA-activated	NULL
lymphocytes	NULL
,	NULL
IL-2*CD3*®	NULL
cells	NULL
were	NULL
not	NULL
detectable	NULL
of	NULL
activated	NULL
lymphocytes	NULL
(	NULL
A	NULL
)	NULL
PHA-activated	NULL
PBL	NULL
were	NULL
incubated	NULL
in	NULL
triplicate	NULL
cultures	NULL
with	NULL
50	NULL
and	NULL
100	NULL
gg/ml	NULL
!	NULL

of	NULL
native	NULL
LDLs	NULL
(	NULL
open	NULL
symbols	NULL
)	NULL
or	NULL
oxLDLs	NULL
(	NULL
closed	NULL
symbols	NULL
)	NULL
for	NULL
72	NULL
h	NULL
in	NULL
RPMI/2	NULL
%	NULL
LPDS	NULL
.	NULL

The	NULL
percentage	NULL
of	NULL
the	NULL
blast	NULL
population	NULL
(	NULL
squares	NULL
)	NULL
was	NULL
estimated	NULL
by	NULL
cytofluorimetry	NULL
(	NULL
%	NULL
of	NULL
blast	NULL
<	NULL
2	NULL
%	NULL
in	NULL
unstimulated	NULL
PBL	NULL
}	NULL
.	NULL

Cell	NULL
proliferation	NULL
(	NULL
circles	NULL
)	NULL
was	NULL
determined	NULL
by	NULL
[	NULL
°HJthymidine	NULL
uptake	NULL
(	NULL
c.p.m	NULL
.	NULL

<	NULL
500	NULL
in	NULL
unstimulated	NULL
PBL	NULL
)	NULL
.	NULL

The	NULL
results	NULL
are	NULL
the	NULL
mean	NULL
+	NULL
S.D	NULL
.	NULL

for	NULL
three	NULL
independent	NULL
experiments	NULL
performed	NULL
with	NULL
PBL	NULL
from	NULL
different	NULL
donors	NULL
.	NULL

(	NULL
B	NULL
)	NULL
PBL	NULL
were	NULL
activated	NULL
by	NULL
PHA	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
3€	NULL
)	NULL
or	NULL
presence	NULL
of	NULL
50	NULL
g/m	NULL
!	NULL

(	NULL
(	NULL
]	NULL
)	NULL
and	NULL
100	NULL
pg/ml	NULL
(	NULL
)	NULL
native	NULL
LDLs	NULL
or	NULL
50	NULL
g/m	NULL
!	NULL

(	NULL
RRI	NULL
)	NULL
and	NULL
100	NULL
g/ml	NULL
(	NULL
@	NULL
)	NULL
oxLDLs	NULL
for	NULL
24	NULL
,	NULL
48	NULL
and	NULL
72	NULL
h	NULL
in	NULL
RPMI/2	NULL
%	NULL
LPDS	NULL
.	NULL

Results	NULL
are	NULL
expressed	NULL
as	NULL
means	NULL
of	NULL
triplicate	NULL
determinations	NULL
of	NULL
blast-cell	NULL
percentage	NULL
.	NULL

A	NULL
second	NULL
experiment	NULL
performed	NULL
with	NULL
a	NULL
different	NULL
donor	NULL
gave	NULL
identical	NULL
results	NULL
.	NULL

(	NULL
C	NULL
)	NULL
PBL	NULL
in	NULL
triplicate	NULL
cultures	NULL
were	NULL
(	NULL
i	NULL
)	NULL
co-incubated	NULL
for	NULL
96	NULL
h	NULL
with	NULL
PHA-4-10	NULL
,	NULL
50	NULL
and	NULL
100	NULL
gg/ml	NULL
of	NULL
native	NULL
LDLs	NULL
(	NULL
)	NULL
or	NULL
oxLDLs	NULL
(	NULL
@	NULL
)	NULL
,	NULL
(	NULL
ii	NULL
)	NULL
pre-incubated	NULL
for	NULL
24	NULL
h	NULL
with	NULL
10	NULL
,	NULL
50	NULL
and	NULL
100	NULL
gg/ml	NULL
of	NULL
native	NULL
LDLs	NULL
(	NULL
[	NULL
C	NULL
]	NULL
)	NULL
or	NULL
oxLDLs	NULL
(	NULL
BB	NULL
)	NULL
,	NULL
washed	NULL
three	NULL
times	NULL
,	NULL
activated	NULL
by	NULL
PHA	NULL
and	NULL
cultured	NULL
for	NULL
72	NULL
h.	NULL
Proliferation	NULL
was	NULL
estimated	NULL
by	NULL
determination	NULL
of	NULL
[	NULL
PH	NULL
uptake	NULL
.	NULL

Results	NULL
are	NULL
expressed	NULL
as	NULL
percentage	NULL
of	NULL
the	NULL
control	NULL
and	NULL
are	NULL
means	NULL
for	NULL
two	NULL
independent	NULL
experiments	NULL
performed	NULL
with	NULL
PBL	NULL
from	NULL
different	NULL
donors	NULL
.	NULL

(	NULL
D	NULL
)	NULL
PBL	NULL
were	NULL
co-incubated	NULL
with	NULL
PHA	NULL
and	NULL
10	NULL
,	NULL
50	NULL
and	NULL
100	NULL
pg/ml	NULL
oxLDLs	NULL
for	NULL
24	NULL
h	NULL
,	NULL
washed	NULL
three	NULL
times	NULL
and	NULL
incubated	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
squares	NULL
)	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
(	NULL
circles	NULL
)	NULL
of	NULL
oxLDLs	NULL
for	NULL
48	NULL
h.	NULL
Results	NULL
are	NULL
expressed	NULL
as	NULL
c.p.m..	NULL
A	NULL
second	NULL
experiment	NULL
performed	NULL
with	NULL
PBL	NULL
from	NULL
a	NULL
different	NULL
donor	NULL
gave	NULL
similar	NULL
results	NULL
.	NULL

before	NULL
8	NULL
h	NULL
by	NULL
flow	NULL
cytometry	NULL
(	NULL
results	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

So	NULL
we	NULL
have	NULL
used	NULL
a	NULL
stronger	NULL
stimulator	NULL
of	NULL
IL-2	NULL
secretion	NULL
,	NULL
i.e	NULL
.	NULL

PMA	NULL
+	NULL
ionomycin	NULL
.	NULL

When	NULL
PBL	NULL
were	NULL
activated	NULL
by	NULL
PMA	NULL
+	NULL
ionomycin	NULL
,	NULL
the	NULL
concentration	NULL
of	NULL
IL-2	NULL
in	NULL
the	NULL
supernatant	NULL
was	NULL
much	NULL
higher	NULL
than	NULL
that	NULL
observed	NULL
after	NULL
PHA	NULL
activation	NULL
(	NULL
Figure	NULL
2C	NULL
)	NULL
.	NULL

However	NULL
,	NULL
the	NULL
inhibitory	NULL
effect	NULL
of	NULL
oxLDLs	NULL
was	NULL
very	NULL
similar	NULL
to	NULL
that	NULL
observed	NULL
in	NULL
the	NULL
case	NULL
of	NULL
activation	NULL
by	NULL
PHA	NULL
and	NULL
was	NULL
already	NULL
appreciable	NULL
by	NULL
24	NULL
h.	NULL
Cytofluorimetric	NULL
analysis	NULL
detected	NULL
a	NULL
significant	NULL
signal	NULL
as	NULL
soon	NULL
as	NULL
4	NULL
h	NULL
after	NULL
stimulation	NULL
:	NULL
17+4	NULL
%	NULL
of	NULL
IL-2*CD3+*	NULL
positive	NULL
cells	NULL
(	NULL
versus	NULL
0.6+0.3	NULL
%	NULL
in	NULL
unactivated-CD3+*	NULL
lymphocytes	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Figure	NULL
2	NULL
(	NULL
D	NULL
)	NULL
,	NULL
the	NULL
IL-2+*	NULL
T-cell	NULL
percentage	NULL
significantly	NULL
decreased	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
oxLDLs	NULL
(	NULL
50	NULL
and	NULL
100	NULL
ug/ml	NULL
)	NULL
as	NULL
compared	NULL
with	NULL
cells	NULL
incubated	NULL
with	NULL
LDLs	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
the	NULL
decrease	NULL
of	NULL
IL-2	NULL
secretion	NULL
induced	NULL
by	NULL
oxLDLs	NULL
can	NULL
directly	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
inhibition	NULL
of	NULL
pro-liferation	NULL
,	NULL
we	NULL
added	NULL
recombinant	NULL
IL-2	NULL
to	NULL
the	NULL
cultures	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Figure	NULL
3	NULL
,	NULL
the	NULL
addition	NULL
of	NULL
IL-2	NULL
stimulated	NULL
DNA	NULL
synthesis	NULL
when	NULL
PHA-activated	NULL
lymphocytes	NULL
were	NULL
cultured	NULL
without	NULL
or	NULL
with	NULL
oxLDLs	NULL
for	NULL
72	NULL
h.	NULL
The	NULL
proliferation	NULL
increased	NULL
as	NULL
a	NULL
function	NULL
of	NULL
the	NULL
IL-2	NULL
concentration	NULL
in	NULL
control	NULL
cultures	NULL
and	NULL
in	NULL
cultures	NULL
with	NULL
50	NULL
ug/ml	NULL
oxLDLs	NULL
,	NULL
but	NULL
seemed	NULL
to	NULL
reach	NULL
a	NULL
limit	NULL
when	NULL
the	NULL
activated	NULL
lymphocytes	NULL
were	NULL
cultured	NULL
with	NULL
100	NULL
ug/ml	NULL
oxLDLs	NULL
.	NULL

The	NULL
same	NULL
results	NULL
were	NULL
obtained	NULL
when	NULL
IL-2	NULL
was	NULL
added	NULL
24	NULL
h	NULL
272	NULL
S.	NULL
Caspar-Bauguil	NULL
and	NULL
others	NULL
A	NULL
1	NULL
B	NULL
404	NULL
4	NULL
4	NULL
g	NULL
191	NULL
€	NULL
x	NULL
T	NULL
§	NULL
r	NULL
g	NULL
3	NULL
1004	NULL
of	NULL
204	NULL
«	NULL
4	NULL
&	NULL
I	NULL
*	NULL
i	NULL
L	NULL
I-	NULL
5	NULL
3	NULL
so	NULL
4	NULL
+	NULL
1	NULL
5	NULL
£	NULL
fam	NULL
..S	NULL
l	NULL
e	NULL
0	NULL
7	NULL
+	NULL
h	NULL
o	NULL
0	NULL
24	NULL
48	NULL
72	NULL
nat	NULL
-	NULL
UV	NULL
-	NULL
Cu	NULL
-	NULL
nat	NULL
UV	NULL
Cu	NULL
+	NULL
L________J	NULL
Time	NULL
(	NULL
h	NULL
)	NULL
100	NULL
ug/ml	NULL
200	NULL
ugimi	NULL
1500	NULL
4	NULL
e	NULL
®	NULL
a	NULL
1007	NULL
T	NULL
D	NULL
P	NULL
*	NULL
T	NULL
-	NULL
o	NULL
B	NULL
1000	NULL
é	NULL
?	NULL

f	NULL
o	NULL
1	NULL
P	NULL
6	NULL
:	NULL
a	NULL
%	NULL
€	NULL
504	NULL
=	NULL
!	NULL

o	NULL
0	NULL
pies	NULL
so0	NULL
-	NULL
<	NULL
e	NULL
&	NULL
aA	NULL
6	NULL
0	NULL
-	NULL
+	NULL
o	NULL
0	NULL
24	NULL
48	NULL
so	NULL
100	NULL
Time	NULL
(	NULL
h	NULL
)	NULL
apoB	NULL
(	NULL
ug/ml	NULL
)	NULL
Figure	NULL
2	NULL
Effect	NULL
of	NULL
oxLDLs	NULL
on	NULL
the	NULL
early	NULL
IL-2	NULL
production	NULL
In	NULL
activated	NULL
T-lymphocytes	NULL
(	NULL
A	NULL
)	NULL
PBL	NULL
were	NULL
activated	NULL
by	NULL
PHA	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
36	NULL
)	NULL
or	NULL
presence	NULL
of	NULL
100	NULL
g/m	NULL
!	NULL

(	NULL
C	NULL
]	NULL
)	NULL
and	NULL
200	NULL
g/ml	NULL
(	NULL
C	NULL
)	NULL
native	NULL
LDLs	NULL
or	NULL
100	NULL
gg/ml	NULL
(	NULL
IRR	NULL
)	NULL
and	NULL
200	NULL
g/m	NULL
!	NULL

(	NULL
@	NULL
)	NULL
oxLDLs	NULL
in	NULL
RPMI/2	NULL
%	NULL
LPDS	NULL
.	NULL

IL-2	NULL
was	NULL
detected	NULL
by	NULL
an	NULL
ELISA	NULL
method	NULL
in	NULL
culture	NULL
supernatants	NULL
after	NULL
24	NULL
,	NULL
48	NULL
and	NULL
72	NULL
h	NULL
of	NULL
culture	NULL
(	NULL
IL-2	NULL
<	NULL
0.8	NULL
pg/m	NULL
!	NULL

in	NULL
unstimulated	NULL
PBL	NULL
at	NULL
24	NULL
,	NULL
48	NULL
or	NULL
72	NULL
h	NULL
)	NULL
.	NULL

Results	NULL
are	NULL
the	NULL
means	NULL
+	NULL
$	NULL
.D	NULL
.	NULL

from	NULL
four	NULL
independent	NULL
experiments	NULL
performed	NULL
with	NULL
lymphocytes	NULL
from	NULL
different	NULL
donors	NULL
.	NULL

(	NULL
B	NULL
)	NULL
PHA-activated	NULL
PBL	NULL
were	NULL
incubated	NULL
for	NULL
24	NULL
h	NULL
in	NULL
RPMI/2	NULL
%	NULL
LPDS	NULL
with	NULL
100	NULL
g/ml	NULL
or	NULL
200	NULL
g/m	NULL
!	NULL

native	NULL
LDLs	NULL
(	NULL
nat	NULL
,	NULL
[	NULL
C	NULL
]	NULL
)	NULL
,	NULL
UV-oxidized	NULL
(	NULL
UV	NULL
,	NULL
RRB	NULL
)	NULL
or	NULL
2	NULL
h-Cu-oxidized	NULL
(	NULL
Cu	NULL
,	NULL
LDLs	NULL
and	NULL
IL-2	NULL
was	NULL
measured	NULL
in	NULL
the	NULL
culture	NULL
supernatants	NULL
.	NULL

Results	NULL
are	NULL
shown	NULL
as	NULL
percentage	NULL
of	NULL
the	NULL
PHA-activated	NULL
control	NULL
without	NULL
LDLs	NULL
and	NULL
are	NULL
means	NULL
for	NULL
three	NULL
independent	NULL
experiments	NULL
,	NULL
each	NULL
performed	NULL
with	NULL
a	NULL
different	NULL
donor	NULL
{	NULL
*P	NULL
<	NULL
0.05	NULL
versus	NULL
control	NULL
cells	NULL
,	NULL
Student	NULL
's	NULL
ftest	NULL
)	NULL
.	NULL

(	NULL
G	NULL
)	NULL
IL-2	NULL
was	NULL
detected	NULL
in	NULL
the	NULL
culture	NULL
supernatants	NULL
of	NULL
PBL	NULL
activated	NULL
by	NULL
PMA	NULL
--	NULL
lonomycin	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
36	NULL
)	NULL
or	NULL
presence	NULL
of	NULL
100	NULL
ag/m	NULL
!	NULL

(	NULL
C	NULL
]	NULL
)	NULL
and	NULL
200	NULL
g/m	NULL
!	NULL

(	NULL
C	NULL
)	NULL
native	NULL
LDLs	NULL
or	NULL
100	NULL
g/ml	NULL
(	NULL
RBR	NULL
)	NULL
and	NULL
200	NULL
g/m	NULL
!	NULL

(	NULL
@	NULL
)	NULL
oxLDLs	NULL
for	NULL
48	NULL
h.	NULL
Results	NULL
are	NULL
means	NULL
for	NULL
two	NULL
independent	NULL
experiments	NULL
performed	NULL
with	NULL
lymphocytes	NULL
from	NULL
different	NULL
donors	NULL
.	NULL

(	NULL
D	NULL
)	NULL
PBL	NULL
were	NULL
activated	NULL
by	NULL
PMA	NULL
+	NULL
ionomycin	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
50	NULL
g/ml	NULL
and	NULL
100	NULL
gg/ml	NULL
native	NULL
LDLs	NULL
(	NULL
[	NULL
C	NULL
]	NULL
)	NULL
or	NULL
oxLDLs	NULL
(	NULL
RN	NULL
)	NULL
for	NULL
4	NULL
h	NULL
in	NULL
RPMI/2	NULL
%	NULL
LPDS	NULL
.	NULL

Intracellular	NULL
IL-2	NULL
was	NULL
detected	NULL
in	NULL
CD3*	NULL
lymphocyte	NULL
population	NULL
by	NULL
cytofluorimetry	NULL
.	NULL

The	NULL
percentage	NULL
of	NULL
IL-2*CD3*	NULL
cells	NULL
was	NULL
determined	NULL
.	NULL

Results	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
percentage	NULL
of	NULL
control	NULL
without	NULL
LDLs	NULL
and	NULL
are	NULL
the	NULL
mean+5.D	NULL
.	NULL

for	NULL
five	NULL
independent	NULL
experiments	NULL
performed	NULL
with	NULL
lymphocytes	NULL
from	NULL
different	NULL
donors	NULL
(	NULL
*P	NULL
<	NULL
0.05	NULL
versus	NULL
control	NULL
cells	NULL
or	NULL
LDL-treated	NULL
cells	NULL
,	NULL
Student	NULL
's	NULL
f	NULL
test	NULL
)	NULL
.	NULL

after	NULL
the	NULL
beginning	NULL
of	NULL
activation	NULL
(	NULL
results	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
agreement	NULL
with	NULL
our	NULL
previous	NULL
data	NULL
,	NULL
a	NULL
clear	NULL
inhibition	NULL
of	NULL
CD25	NULL
expression	NULL
was	NULL
observed	NULL
at	NULL
the	NULL
surface	NULL
of	NULL
CD3*	NULL
lymphocytes	NULL
incubated	NULL
with	NULL
50	NULL
and	NULL
100	NULL
ug/ml	NULL
oxLDLs	NULL
(	NULL
Figure	NULL
3	NULL
,	NULL
inset	NULL
)	NULL
.	NULL

The	NULL
decreased	NULL
T-cell	NULL
proliferation	NULL
is	NULL
thus	NULL
partly	NULL
explained	NULL
by	NULL
a	NULL
relative	NULL
lack	NULL
of	NULL
IL-2	NULL
and	NULL
a	NULL
decreased	NULL
IL-2	NULL
receptor	NULL
expression	NULL
at	NULL
the	NULL
surface	NULL
of	NULL
the	NULL
lymphocytes	NULL
.	NULL

Effect	NULL
of	NULL
oxLDLs	NULL
on	NULL
the	NULL
binding	NULL
of	NULL
NF-xB	NULL
to	NULL
DNA	NULL
in	NULL
activated	NULL
PBL	NULL
The	NULL
results	NULL
mentioned	NULL
above	NULL
suggest	NULL
that	NULL
oxLDLs	NULL
may	NULL
act	NULL
before	NULL
4	NULL
h	NULL
on	NULL
events	NULL
induced	NULL
by	NULL
T-lymphocyte	NULL
stimulation	NULL
.	NULL

The	NULL
activation	NULL
of	NULL
T-lymphocytes	NULL
by	NULL
antigens	NULL
and	NULL
mitogens	NULL
triggers	NULL
the	NULL
early	NULL
trans-activation	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
,	NULL
which	NULL
depends	NULL
on	NULL
the	NULL
binding	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
to	NULL
specific	NULL
DNA	NULL
sites	NULL
.	NULL

We	NULL
have	NULL
examined	NULL
the	NULL
translocation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
to	NULL
the	NULL
nucleus	NULL
by	NULL
EMSA	NULL
after	NULL
activation	NULL
of	NULL
PBL	NULL
by	NULL
PHA	NULL
or	NULL
PMA-+ionomycin	NULL
.	NULL

In	NULL
agreement	NULL
with	NULL
previous	NULL
studies	NULL
[	NULL
28,30,31	NULL
]	NULL
,	NULL
nuclear	NULL
extracts	NULL
from	NULL
resting	NULL
lymphocytes	NULL
contained	NULL
a	NULL
constitutive	NULL
nuclear	NULL
band	NULL
corresponding	NULL
to	NULL
p50/p50	NULL
homodimers	NULL
(	NULL
Figure	NULL
4A	NULL
)	NULL
.	NULL

PHA	NULL
or	NULL
PMA	NULL
+ionomycin	NULL
500	NULL
-	NULL
CD3+ast+	NULL
7500	NULL
-	NULL
©	NULL
z	NULL
400+	NULL
u	NULL
A	NULL
300-7	NULL
O	NULL
200	NULL
-|	NULL
U	NULL
I	NULL
I	NULL
%	NULL
o	NULL
-	NULL
so	NULL
100	NULL
$	NULL
3	NULL
5000	NULL
-	NULL
apo	NULL
B	NULL
(	NULL
ug/m	NULL
!	NULL
)	NULL

O	NULL
haa	NULL
~	NULL
E	NULL
o	NULL
O	NULL
2500	NULL
0	NULL
0	NULL
50	NULL
100	NULL
apo	NULL
B	NULL
(	NULL
ug/m	NULL
!	NULL
)	NULL

Figure	NULL
3	NULL
Addition	NULL
of	NULL
IL-2	NULL
In	NULL
cultures	NULL
of	NULL
PHA-activated	NULL
lymphocytes	NULL
co-Incubated	NULL
with	NULL
oxLDLs	NULL
PHA-activated	NULL
PBL	NULL
were	NULL
cultured	NULL
in	NULL
triplicate	NULL
with	NULL
50	NULL
g/m	NULL
!	NULL

and	NULL
100	NULL
zg/m	NULL
!	NULL

of	NULL
oxLDLs	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
RW	NULL
)	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
50	NULL
units/ml	NULL
(	NULL
4000	NULL
pg/m	NULL
!	NULL
)	NULL

(	NULL
@	NULL
@	NULL
)	NULL
and	NULL
200	NULL
units/ml	NULL
(	NULL
16000	NULL
pg/m	NULL
!	NULL
)	NULL

(	NULL
[	NULL
C	NULL
]	NULL
)	NULL
of	NULL
recombinant	NULL
IL-2	NULL
for	NULL
72	NULL
h	NULL
in	NULL
RPMI/2	NULL
%	NULL
LPDS	NULL
.	NULL

Cell	NULL
proliferation	NULL
was	NULL
estimated	NULL
by	NULL
determination	NULL
of	NULL
[	NULL
H	NULL
]	NULL
thymidine	NULL
uptake	NULL
.	NULL

Results	NULL
are	NULL
means	NULL
of	NULL
triplicate	NULL
determinations	NULL
.	NULL

One	NULL
other	NULL
separate	NULL
experiment	NULL
,	NULL
performed	NULL
with	NULL
a	NULL
different	NULL
donor	NULL
,	NULL
gave	NULL
identical	NULL
results	NULL
.	NULL

In	NULL
the	NULL
inset	NULL
is	NULL
shown	NULL
the	NULL
expression	NULL
of	NULL
CD25	NULL
in	NULL
PHA-activated	NULL
CD3+*	NULL
T-lymphocytes	NULL
cultured	NULL
for	NULL
72	NULL
h	NULL
with	NULL
oxLDLs	NULL
.	NULL

The	NULL
results	NULL
are	NULL
expressed	NULL
as	NULL
CD25	NULL
mean	NULL
fluorescence	NULL
intensity	NULL
(	NULL
MF	NULL
)	NULL
in	NULL
double-positive	NULL
populations	NULL
activation	NULL
induced	NULL
the	NULL
decrease	NULL
of	NULL
the	NULL
p50/p50	NULL
homodimer	NULL
band	NULL
and	NULL
the	NULL
emergence	NULL
of	NULL
a	NULL
new	NULL
retarded	NULL
band	NULL
corresponding	NULL
to	NULL
the	NULL
binding	NULL
of	NULL
the	NULL
oligonucleotide	NULL
with	NULL
the	NULL
p65/p50	NULL
heterodimer	NULL
.	NULL

This	NULL
later	NULL
dimer	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
IL-2	NULL
and	NULL
CD25	NULL
genes	NULL
after	NULL
stimulation	NULL
of	NULL
T-cells	NULL
with	NULL
antigens	NULL
,	NULL
anti-CD3	NULL
antibodies	NULL
,	NULL
PHA	NULL
or	NULL
PMA	NULL
+	NULL
ionomycin	NULL
[	NULL
28,30,31	NULL
]	NULL
.	NULL

When	NULL
lymphocytes	NULL
were	NULL
exposed	NULL
simultaneously	NULL
to	NULL
oxLDLs	NULL
and	NULL
activator	NULL
,	NULL
the	NULL
intensity	NULL
of	NULL
this	NULL
last	NULL
band	NULL
decreased	NULL
whereas	NULL
the	NULL
p50/p50	NULL
homodimer	NULL
band	NULL
was	NULL
unchanged	NULL
.	NULL

Figure	NULL
4	NULL
(	NULL
B	NULL
)	NULL
shows	NULL
the	NULL
spec-ificity	NULL
of	NULL
the	NULL
p65/p50	NULL
heterodimer	NULL
as	NULL
supershifts	NULL
revealed	NULL
by	NULL
a	NULL
preincubation	NULL
with	NULL
specific	NULL
anti-p65	NULL
and	NULL
anti-p50	NULL
antibodies	NULL
and	NULL
competition	NULL
with	NULL
an	NULL
irrelevant	NULL
unlabelled	NULL
oligonucleotide	NULL
(	NULL
AP1	NULL
)	NULL
and	NULL
the	NULL
specific	NULL
unlabelled	NULL
NF-	NULL
«	NULL
B	NULL
oligonucleotide	NULL
.	NULL

Since	NULL
exposure	NULL
to	NULL
oxLDLs	NULL
seemed	NULL
to	NULL
inhibit	NULL
the	NULL
NF-kB	NULL
activation	NULL
induced	NULL
by	NULL
PHA	NULL
or	NULL
PMA	NULL
+	NULL
ionomycin	NULL
in	NULL
lymphocytes	NULL
,	NULL
the	NULL
role	NULL
of	NULL
the	NULL
inhibitor	NULL
IxB-	NULL
«	NULL
was	NULL
examined	NULL
in	NULL
the	NULL
same	NULL
experimental	NULL
conditions	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
lymphocyte	NULL
activation	NULL
led	NULL
to	NULL
a	NULL
rapid	NULL
proteolytic	NULL
removal	NULL
of	NULL
IxB-a	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
lipoproteins	NULL
.	NULL

This	NULL
proteolysis	NULL
was	NULL
not	NULL
modified	NULL
by	NULL
LDLs	NULL
,	NULL
whereas	NULL
oxLDLs	NULL
clearly	NULL
blocked	NULL
the	NULL
cytoplasmic	NULL
depletion	NULL
of	NULL
I	NULL
«	NULL
xB-a	NULL
(	NULL
Figure	NULL
4C	NULL
)	NULL
.	NULL

DISCUSSION	NULL
The	NULL
present	NULL
data	NULL
demonstrate	NULL
that	NULL
mildly	NULL
oxLDLs	NULL
inhibit	NULL
the	NULL
blastic	NULL
transformation	NULL
of	NULL
PHA-activated	NULL
lymphocytes	NULL
.	NULL

This	NULL
is	NULL
in	NULL
agreement	NULL
with	NULL
our	NULL
previous	NULL
work	NULL
showing	NULL
an	NULL
inhibition	NULL
of	NULL
DNA	NULL
synthesis	NULL
and	NULL
an	NULL
accumulation	NULL
of	NULL
cells	NULL
at	NULL
the	NULL
G	NULL
,	NULL
-phase/S-phase	NULL
interface	NULL
in	NULL
activated	NULL
T-lymphocytes	NULL
[	NULL
9	NULL
]	NULL
.	NULL

While	NULL
the	NULL
24	NULL
h	NULL
preincubation	NULL
of	NULL
naive	NULL
lymphocytes	NULL
with	NULL
oxLDLs	NULL
did	NULL
not	NULL
inhibit	NULL
T-lymphocyte	NULL
activation	NULL
and	NULL
oxidized	NULL
low-density	NULL
lipoproteins	NULL
213	NULL
C	NULL
#	NULL
4	NULL
IKB	NULL
|	NULL
-	NULL
»	NULL
«	NULL
4	NULL
.	NULL

P	NULL
65	NULL
/p	NULL
50	NULL
uy	NULL
+p50fp50_h	NULL
,	NULL
1	NULL
2	NULL
3	NULL
4	NULL
gpa	NULL
4	NULL
(	NULL
)	NULL
actin	NULL
_	NULL
=p	NULL
|	NULL
*	NULL
>	NULL
Supershift	NULL
g.	NULL
SUP	NULL
l	NULL
“	NULL
+	NULL
«	NULL
g	NULL
.	NULL

-	NULL
p	NULL
50/p	NULL
50	NULL
p	NULL
65	NULL
/p	NULL
50	NULL
Figure	NULL
4	NULL
-	NULL
Effect	NULL
of	NULL
oxLDLs	NULL
on	NULL
activation	NULL
of	NULL
NF-xB	NULL
In	NULL
stimulated	NULL
lymphocytes	NULL
(	NULL
A	NULL
)	NULL
At	NULL
the	NULL
left	NULL
,	NULL
PBL	NULL
were	NULL
activated	NULL
by	NULL
PHA	NULL
for	NULL
60	NULL
min	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
or	NULL
the	NULL
presence	NULL
of	NULL
100	NULL
g/m	NULL
!	NULL

native	NULL
LDLs	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
or	NULL
oxLDLs	NULL
{	NULL
lane	NULL
4	NULL
)	NULL
.	NULL

At	NULL
the	NULL
right	NULL
,	NULL
PBL	NULL
were	NULL
activated	NULL
by	NULL
PMA	NULL
+	NULL
ionomycin	NULL
for	NULL
15	NULL
min	NULL
without	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
or	NULL
with	NULL
100	NULL
native	NULL
LDLs	NULL
(	NULL
lane	NULL
7	NULL
)	NULL
or	NULL
oxLDLs	NULL
(	NULL
lane	NULL
8	NULL
)	NULL
.	NULL

In	NULL
lanes	NULL
1	NULL
and	NULL
5	NULL
are	NULL
unstimulated	NULL
PBL	NULL
.	NULL

Nuclear	NULL
p65p50	NULL
and	NULL
p50p50	NULL
dimers	NULL
were	NULL
detected	NULL
by	NULL
EMSA	NULL
with	NULL
the	NULL
consensus-specific	NULL
NF-xB	NULL
oligonucleotide	NULL
labelled	NULL
with	NULL
[	NULL
y-SZP	NULL
]	NULL
ATP	NULL
.	NULL

The	NULL
data	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
performed	NULL
with	NULL
lymphocytes	NULL
from	NULL
different	NULL
donors	NULL
.	NULL

(	NULL
B	NULL
)	NULL
PBL	NULL
were	NULL
activated	NULL
by	NULL
PMA-+-ionomycin	NULL
for	NULL
15	NULL
min	NULL
.	NULL

Nuclear	NULL
NF-B	NULL
proteins	NULL
were	NULL
detected	NULL
directly	NULL
with	NULL
the	NULL
consensus-labelled	NULL
NF-xB	NULL
oligonucleotide	NULL
(	NULL
lang	NULL
1	NULL
)	NULL
or	NULL
after	NULL
a	NULL
30	NULL
min	NULL
preincubation	NULL
of	NULL
nuclear	NULL
proteins	NULL
with	NULL
1	NULL
zeg	NULL
of	NULL
specific	NULL
anti-p65	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
or	NULL
anti-p50	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
antibodies	NULL
,	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
unlabelled	NULL
irrelevant	NULL
AP1	NULL
oligonucleotide	NULL
(	NULL
lang	NULL
4	NULL
)	NULL
or	NULL
100-fold	NULL
molar	NULL
excess	NULL
of	NULL
unlabelled	NULL
NF-B	NULL
oligonucleotide	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

The	NULL
data	NULL
are	NULL
representative	NULL
of	NULL
two	NULL
independent	NULL
experiments	NULL
performed	NULL
with	NULL
lymphocytes	NULL
from	NULL
different	NULL
donors	NULL
.	NULL

Similar	NULL
results	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
were	NULL
observed	NULL
after	NULL
PHA	NULL
activation	NULL
.	NULL

(	NULL
C	NULL
)	NULL
The	NULL
PBL	NULL
were	NULL
activated	NULL
in	NULL
the	NULL
same	NULL
way	NULL
as	NULL
described	NULL
for	NULL
(	NULL
A	NULL
)	NULL
.	NULL

The	NULL
cytoplasmic	NULL
I	NULL
«	NULL
B-	NULL
«	NULL
protein	NULL
(	NULL
IxB	NULL
)	NULL
and	NULL
the	NULL
control	NULL
Z-actin	NULL
were	NULL
detected	NULL
by	NULL
Western	NULL
blot	NULL
using	NULL
a	NULL
specific	NULL
antibody	NULL
.	NULL

The	NULL
data	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
performed	NULL
with	NULL
lymphocytes	NULL
from	NULL
different	NULL
donors	NULL
.	NULL

the	NULL
subsequent	NULL
proliferative	NULL
response	NULL
to	NULL
PHA	NULL
,	NULL
a	NULL
similar	NULL
incubation	NULL
of	NULL
activated	NULL
lymphocytes	NULL
induced	NULL
a	NULL
maximal	NULL
inhibition	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
sensitivity	NULL
to	NULL
OxLDLs	NULL
depends	NULL
on	NULL
the	NULL
activation	NULL
state	NULL
of	NULL
lymphocytes	NULL
(	NULL
Figure	NULL
1D	NULL
)	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
shown	NULL
that	NULL
oxLDLs	NULL
inhibit	NULL
the	NULL
expression	NULL
of	NULL
CD25	NULL
24	NULL
h	NULL
after	NULL
lymphocyte	NULL
activation	NULL
by	NULL
PHA	NULL
,	NULL
whereas	NULL
the	NULL
expression	NULL
of	NULL
CD69	NULL
and	NULL
HLA-DR	NULL
is	NULL
unchanged	NULL
.	NULL

The	NULL
present	NULL
work	NULL
demonstrates	NULL
that	NULL
IL-2	NULL
synthesis	NULL
was	NULL
also	NULL
inhibited	NULL
by	NULL
oxLDLs	NULL
.	NULL

This	NULL
effect	NULL
is	NULL
time-	NULL
and	NULL
dose-dependent	NULL
and	NULL
correlates	NULL
with	NULL
the	NULL
level	NULL
of	NULL
LDL	NULL
oxidation	NULL
at	NULL
the	NULL
time	NULL
of	NULL
activation	NULL
.	NULL

The	NULL
decrease	NULL
in	NULL
intracytoplasmic	NULL
IL-2	NULL
level	NULL
in	NULL
CD3*	NULL
T-lymphocytes	NULL
can	NULL
be	NULL
demonstrated	NULL
as	NULL
soon	NULL
as	NULL
4	NULL
h	NULL
after	NULL
stimulation	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
data	NULL
suggest	NULL
that	NULL
the	NULL
suppressive	NULL
effect	NULL
of	NULL
oxLDLs	NULL
on	NULL
T-lymphocyte	NULL
proliferation	NULL
is	NULL
a	NULL
consequence	NULL
of	NULL
the	NULL
inhibition	NULL
of	NULL
IL-2	NULL
secretion	NULL
and	NULL
of	NULL
the	NULL
impairment	NULL
of	NULL
CD25	NULL
expression	NULL
,	NULL
since	NULL
the	NULL
interaction	NULL
of	NULL
IL-2	NULL
with	NULL
its	NULL
receptor	NULL
is	NULL
usually	NULL
required	NULL
for	NULL
activated	NULL
T-lymphocytes	NULL
to	NULL
progress	NULL
from	NULL
the	NULL
G	NULL
,	NULL
-	NULL
to	NULL
the	NULL
S-phase	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
[	NULL
29	NULL
]	NULL
.	NULL

During	NULL
T-cell	NULL
activation	NULL
,	NULL
the	NULL
expression	NULL
of	NULL
IL-2	NULL
and	NULL
CD25	NULL
genes	NULL
is	NULL
one	NULL
of	NULL
the	NULL
earliest	NULL
events	NULL
.	NULL

This	NULL
gene	NULL
expression	NULL
involves	NULL
several	NULL
identified	NULL
nuclear	NULL
complexes	NULL
such	NULL
as	NULL
NF-	NULL
«	NULL
B	NULL
,	NULL
AP-1	NULL
,	NULL
NF-AT	NULL
[	NULL
25,29-31	NULL
]	NULL
.	NULL

The	NULL
present	NULL
data	NULL
strongly	NULL
suggest	NULL
that	NULL
oxLDLs	NULL
might	NULL
inhibit	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
two	NULL
proteins	NULL
(	NULL
IL-2	NULL
and	NULL
CD25	NULL
)	NULL
,	NULL
because	NULL
they	NULL
alter	NULL
,	NULL
at	NULL
least	NULL
partly	NULL
,	NULL
the	NULL
transcription	NULL
mechanisms	NULL
involving	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
family	NULL
.	NULL

Indeed	NULL
,	NULL
oxLDLs	NULL
(	NULL
100	NULL
ug/ml	NULL
)	NULL
down-regulated	NULL
the	NULL
activation-induced	NULL
binding	NULL
of	NULL
p65/p50	NULL
heterodimers	NULL
to	NULL
a	NULL
consensus	NULL
sequence	NULL
of	NULL
DNA	NULL
and	NULL
maintained	NULL
the	NULL
nuclear	NULL
presence	NULL
of	NULL
p50	NULL
dimers	NULL
probably	NULL
involved	NULL
in	NULL
the	NULL
repression	NULL
of	NULL
IL-2-gene	NULL
transcription	NULL
[	NULL
25	NULL
]	NULL
.	NULL

Since	NULL
«	NULL
B	NULL
elements	NULL
have	NULL
been	NULL
found	NULL
on	NULL
the	NULL
promoters	NULL
of	NULL
several	NULL
other	NULL
cytokine	NULL
genes	NULL
in	NULL
lymphocytes	NULL
and	NULL
monocytes	NULL
,	NULL
the	NULL
inhibition	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
system	NULL
might	NULL
also	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
oxLDL-induced	NULL
impairment	NULL
of	NULL
production	NULL
of	NULL
interferon-y	NULL
(	NULL
known	NULL
to	NULL
be	NULL
synthesized	NULL
by	NULL
activated	NULL
T-lymphocytes	NULL
)	NULL
[	NULL
8	NULL
]	NULL
and	NULL
of	NULL
IL-1	NULL
#	NULL
and	NULL
tumour	NULL
necrosis	NULL
factor-	NULL
«	NULL
(	NULL
produced	NULL
by	NULL
activated	NULL
monocytes	NULL
)	NULL
previously	NULL
reported	NULL
[	NULL
6	NULL
]	NULL
.	NULL

The	NULL
effect	NULL
on	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
was	NULL
observed	NULL
immediately	NULL
after	NULL
lymphocyte	NULL
stimulation	NULL
,	NULL
but	NULL
we	NULL
can	NULL
not	NULL
exclude	NULL
the	NULL
possibility	NULL
that	NULL
oxLDLs	NULL
alter	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
at	NULL
later	NULL
time	NULL
points	NULL
and	NULL
thus	NULL
dysregulate	NULL
the	NULL
control	NULL
of	NULL
several	NULL
genes	NULL
encoding	NULL
other	NULL
growth-regulating	NULL
proteins	NULL
[	NULL
30,31	NULL
]	NULL
.	NULL

Indeed	NULL
,	NULL
T-cell	NULL
activation	NULL
induces	NULL
an	NULL
early	NULL
decrease	NULL
in	NULL
the	NULL
level	NULL
of	NULL
p50	NULL
dimers	NULL
in	NULL
the	NULL
nucleus	NULL
and	NULL
a	NULL
concomitant	NULL
increase	NULL
in	NULL
the	NULL
level	NULL
of	NULL
active	NULL
p50/p65	NULL
heterodimers	NULL
[	NULL
24,25,28,30,31	NULL
]	NULL
,	NULL
whereas	NULL
in	NULL
the	NULL
late	NULL
phase	NULL
(	NULL
from	NULL
24	NULL
to	NULL
72	NULL
h	NULL
after	NULL
activation	NULL
)	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
p50	NULL
NF-	NULL
«	NULL
B	NULL
protein	NULL
is	NULL
increased	NULL
progressively	NULL
[	NULL
32	NULL
]	NULL
.	NULL

Our	NULL
data	NULL
demonstrate	NULL
that	NULL
oxLDLs	NULL
inhibit	NULL
the	NULL
activation-induced	NULL
depletion	NULL
of	NULL
the	NULL
IxB-	NULL
«	NULL
protein	NULL
immediately	NULL
after	NULL
stimulation	NULL
.	NULL

In	NULL
resting	NULL
lymphocytes	NULL
,	NULL
IxB-a	NULL
«	NULL
is	NULL
bound	NULL
to	NULL
the	NULL
p50/p65	NULL
heterodimer	NULL
in	NULL
the	NULL
cytoplasm	NULL
.	NULL

When	NULL
lymphocytes	NULL
are	NULL
exposed	NULL
to	NULL
inducers	NULL
of	NULL
NF-kB	NULL
,	NULL
IkB-a	NULL
is	NULL
rapidly	NULL
phosphorylated	NULL
and	NULL
degraded	NULL
by	NULL
the	NULL
proteasome	NULL
,	NULL
whereas	NULL
the	NULL
heterodimer	NULL
is	NULL
trans-located	NULL
[	NULL
26,30	NULL
]	NULL
.	NULL

Our	NULL
results	NULL
suggest	NULL
that	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
inhibition	NULL
could	NULL
be	NULL
explained	NULL
either	NULL
by	NULL
an	NULL
absence	NULL
of	NULL
IxB	NULL
degradation	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
decrease	NULL
of	NULL
its	NULL
proteolysis	NULL
by	NULL
the	NULL
proteasome	NULL
)	NULL
or	NULL
by	NULL
a	NULL
dysregulation	NULL
of	NULL
its	NULL
phosphorylation	NULL
.	NULL

Using	NULL
immunofluorescence	NULL
and	NULL
immunohistochemical	NULL
tech-niques	NULL
,	NULL
activated	NULL
NF-	NULL
«	NULL
B	NULL
has	NULL
been	NULL
detected	NULL
in	NULL
atherosclerotic	NULL
lesions	NULL
in	NULL
smooth-muscle	NULL
cells	NULL
,	NULL
macrophages	NULL
and	NULL
endothelial	NULL
cells	NULL
[	NULL
33	NULL
]	NULL
.	NULL

Several	NULL
recent	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
,	NULL
in	NULL
these	NULL
various	NULL
cell	NULL
types	NULL
,	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
system	NULL
can	NULL
react	NULL
differently	NULL
to	NULL
oxLDLs	NULL
.	NULL

According	NULL
to	NULL
the	NULL
level	NULL
of	NULL
oxidation	NULL
of	NULL
LDLs	NULL
,	NULL
the	NULL
cell	NULL
type	NULL
and/or	NULL
the	NULL
activation	NULL
state	NULL
of	NULL
the	NULL
cells	NULL
,	NULL
oxLDLs	NULL
may	NULL
activate	NULL
or	NULL
inhibit	NULL
NF-	NULL
«	NULL
B	NULL
[	NULL
3,6,34,35	NULL
]	NULL
.	NULL

For	NULL
instance	NULL
,	NULL
a	NULL
short	NULL
exposure	NULL
to	NULL
oxLDLs	NULL
can	NULL
activate	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
resting	NULL
monocytes	NULL
and	NULL
be	NULL
accompanied	NULL
by	NULL
an	NULL
increase	NULL
of	NULL
IL-8-promoter-dependent	NULL
transcription	NULL
[	NULL
3	NULL
]	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
preincubation	NULL
or	NULL
co-incubation	NULL
of	NULL
lipopolysaccharide	NULL
(	NULL
LPS	NULL
)	NULL
-activated	NULL
monocytes	NULL
with	NULL
oxLDLs	NULL
inhibit	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
[	NULL
3,6,35	NULL
]	NULL
.	NULL

Similarly	NULL
,	NULL
in	NULL
vascular	NULL
smooth-muscle	NULL
cells	NULL
,	NULL
oxLDLs	NULL
inhibit	NULL
LPS-induced	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
[	NULL
36	NULL
]	NULL
.	NULL

In	NULL
agreement	NULL
with	NULL
these	NULL
data	NULL
,	NULL
the	NULL
results	NULL
of	NULL
the	NULL
present	NULL
study	NULL
suggest	NULL
that	NULL
oxLDLs	NULL
may	NULL
suppress	NULL
the	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
factors	NULL
in	NULL
lymphocytes	NULL
,	NULL
leading	NULL
to	NULL
the	NULL
subsequent	NULL
inhibition	NULL
of	NULL
274	NULL
S.	NULL
Caspar-Bauguil	NULL
and	NULL
others	NULL
IL-2	NULL
synthesis	NULL
and	NULL
IL-2	NULL
receptor	NULL
expression	NULL
.	NULL

However	NULL
,	NULL
several	NULL
other	NULL
transcription	NULL
factors	NULL
control	NULL
the	NULL
IL-2	NULL
and	NULL
CD25	NULL
gene	NULL
expression	NULL
in	NULL
activated	NULL
lymphocytes	NULL
and	NULL
could	NULL
be	NULL
differently	NULL
altered	NULL
by	NULL
oxLDLs	NULL
.	NULL

A	NULL
recent	NULL
study	NULL
using	NULL
human	NULL
mono-cytes-macrophages	NULL
showed	NULL
that	NULL
oxLDLs	NULL
activate	NULL
transcriptor	NULL
AP1	NULL
[	NULL
37	NULL
]	NULL
.	NULL

Another	NULL
study	NULL
demonstrated	NULL
that	NULL
oxLDLs	NULL
have	NULL
similar	NULL
inhibitory	NULL
effects	NULL
on	NULL
LPS-induced	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
API	NULL
in	NULL
macrophages	NULL
[	NULL
6	NULL
]	NULL
,	NULL
whereas	NULL
others	NULL
suggest	NULL
that	NULL
they	NULL
have	NULL
opposing	NULL
effects	NULL
on	NULL
the	NULL
two	NULL
transcription	NULL
factors	NULL
[	NULL
36	NULL
]	NULL
.	NULL

Preliminary	NULL
results	NULL
in	NULL
our	NULL
laboratory	NULL
indicate	NULL
that	NULL
oxLDLs	NULL
might	NULL
induce	NULL
a	NULL
moderate	NULL
down-modulation	NULL
of	NULL
API	NULL
binding	NULL
to	NULL
DNA	NULL
after	NULL
PHA	NULL
or	NULL
PMA	NULL
+ionomycin-mediated	NULL
activation	NULL
.	NULL

Several	NULL
signal-transduction	NULL
pathways	NULL
may	NULL
lead	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
NF-kB	NULL
proteins	NULL
in	NULL
T-lymphocytes	NULL
.	NULL

For	NULL
example	NULL
,	NULL
PKC-	NULL
and	NULL
Ca**-dependent	NULL
pathways	NULL
participate	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
[	NULL
38	NULL
]	NULL
.	NULL

oOxLDLs	NULL
are	NULL
known	NULL
to	NULL
be	NULL
able	NULL
to	NULL
induce	NULL
various	NULL
intracellular	NULL
transduction	NULL
signals	NULL
in	NULL
endothelial	NULL
cells	NULL
,	NULL
smooth-muscle	NULL
cells	NULL
and	NULL
macrophages	NULL
[	NULL
35,39-42	NULL
]	NULL
.	NULL

Experiments	NULL
are	NULL
in	NULL
progress	NULL
with	NULL
inhibitors	NULL
to	NULL
assess	NULL
the	NULL
putative	NULL
modulating	NULL
effect	NULL
of	NULL
oxLDLs	NULL
on	NULL
various	NULL
signalling	NULL
processes	NULL
.	NULL

It	NULL
is	NULL
not	NULL
known	NULL
which	NULL
factor	NULL
in	NULL
oxLDLs	NULL
is	NULL
responsible	NULL
for	NULL
the	NULL
observed	NULL
effect	NULL
on	NULL
lymphocytes	NULL
.	NULL

Under	NULL
our	NULL
experimental	NULL
con-ditions	NULL
,	NULL
oxLDLs	NULL
are	NULL
mainly	NULL
oxidized	NULL
at	NULL
the	NULL
lipid	NULL
level	NULL
and	NULL
are	NULL
taken	NULL
up	NULL
by	NULL
lymphocytes	NULL
via	NULL
LDL	NULL
receptors	NULL
[	NULL
27	NULL
]	NULL
,	NULL
and	NULL
lipid	NULL
oxidation	NULL
is	NULL
characterized	NULL
by	NULL
no	NULL
significant	NULL
modification	NULL
of	NULL
lysophosphatidylcholine	NULL
content	NULL
,	NULL
and	NULL
a	NULL
moderate	NULL
increase	NULL
of	NULL
oxysterols	NULL
and	NULL
hydroperoxides	NULL
[	NULL
9,43	NULL
]	NULL
.	NULL

It	NULL
has	NULL
been	NULL
suggested	NULL
that	NULL
lipid	NULL
oxidation	NULL
products	NULL
have	NULL
an	NULL
important	NULL
biological	NULL
effect	NULL
on	NULL
transcriptional	NULL
regulation	NULL
.	NULL

For	NULL
instance	NULL
,	NULL
oxysterols	NULL
inhibit	NULL
LPS-induced	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
macrophages	NULL
and	NULL
smooth-muscle	NULL
cells	NULL
[	NULL
6,36	NULL
]	NULL
,	NULL
and	NULL
it	NULL
can	NULL
be	NULL
proposed	NULL
that	NULL
lipid	NULL
oxidation	NULL
products	NULL
such	NULL
as	NULL
oxysterols	NULL
and	NULL
hydroperoxides	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
inhibition	NULL
of	NULL
the	NULL
T-cell	NULL
activation	NULL
.	NULL

The	NULL
present	NULL
results	NULL
indicate	NULL
that	NULL
mildly	NULL
oxLDLs	NULL
may	NULL
dysregulate	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
system	NULL
and	NULL
inhibit	NULL
IL-2	NULL
production	NULL
in	NULL
lymphocytes	NULL
.	NULL

Taken	NULL
together	NULL
with	NULL
our	NULL
previous	NULL
observations	NULL
[	NULL
9	NULL
]	NULL
,	NULL
these	NULL
experiments	NULL
suggest	NULL
that	NULL
oxLDLs	NULL
may	NULL
inhibit	NULL
early	NULL
steps	NULL
of	NULL
the	NULL
T-lymphocyte	NULL
activation	NULL
.	NULL

In	NULL
atherosclerosis	NULL
,	NULL
the	NULL
oxLDLs	NULL
might	NULL
alter	NULL
the	NULL
lymphocyte	NULL
activation	NULL
in	NULL
site	NULL
or	NULL
minimize	NULL
the	NULL
response	NULL
of	NULL
activated	NULL
T-lymphocytes	NULL
,	NULL
which	NULL
migrate	NULL
toward	NULL
the	NULL
lesions	NULL
.	NULL

The	NULL
role	NULL
of	NULL
this	NULL
potential	NULL
immunosuppressive	NULL
effect	NULL
on	NULL
the	NULL
progression	NULL
of	NULL
the	NULL
atherosclerotic	NULL
lesions	NULL
remains	NULL
to	NULL
be	NULL
demonstrated	NULL
in	NULL
vivo	NULL
.	NULL

Since	NULL
recent	NULL
reports	NULL
suggest	NULL
that	NULL
common	NULL
chronic	NULL
infections	NULL
may	NULL
contribute	NULL
to	NULL
the	NULL
pathogenesis	NULL
of	NULL
coronary	NULL
atherosclerosis	NULL
[	NULL
44	NULL
]	NULL
,	NULL
oxLDLs	NULL
might	NULL
impair	NULL
the	NULL
immune	NULL
response	NULL
against	NULL
the	NULL
infections	NULL
of	NULL
the	NULL
vascular	NULL
wall	NULL
and	NULL
thus	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
progression	NULL
of	NULL
the	NULL
atherosclerotic	NULL
lesions	NULL
.	NULL

We	NULL
thank	NULL
Sylvie	NULL
Hebrard	NULL
,	NULL
Jean	NULL
Vandaele	NULL
and	NULL
Virginie	NULL
Garcia	NULL
for	NULL
competent	NULL
technical	NULL
assistance	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
grants	NULL
from	NULL
INSERM	NULL
(	NULL
U	NULL
466	NULL
)	NULL
,	NULL
the	NULL
Région	NULL
Midi-Pyrénées	NULL
,	NULL
the	NULL
'Association	NULL
pour	NULL
la	NULL
Recherche	NULL
contre	NULL
le	NULL
Cancer	NULL
(	NULL
ARC	NULL
)	NULL
,	NULL
the	NULL
'Fondation	NULL
pour	NULL
la	NULL
Recherche	NULL
Médicale	NULL
``	NULL
,	NULL
the	NULL
Université	NULL
Paul	NULL
Sabatier-Toulouse	NULL
3	NULL
(	NULL
JE-174	NULL
)	NULL
and	NULL
the	NULL
European	NULL
Community	NULL
(	NULL
PL	NULL
931790	NULL
)	NULL
.	NULL

We	NULL
are	NULL
grateful	NULL
to	NULL
SANOFI	NULL
for	NULL
generously	NULL
providing	NULL
recombinant	NULL
IL-2	NULL
.	NULL

REFERENCES	NULL
1	NULL
-	NULL
Goldstein	NULL
,	NULL
J.	NULL
L.	NULL
and	NULL
Brown	NULL
,	NULL
M.	NULL
S.	NULL
(	NULL
1977	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Biochem	NULL
.	NULL

46	NULL
,	NULL
897-930	NULL
2	NULL
-	NULL
Witztum	NULL
,	NULL
J.	NULL
L.	NULL
and	NULL
Steinberg	NULL
,	NULL
D.	NULL
(	NULL
1991	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

88	NULL
,	NULL
1785-1792	NULL
3	NULL
-	NULL
Brand	NULL
,	NULL
K.	NULL
,	NULL
Eisele	NULL
,	NULL
T.	NULL
,	NULL
Kreusel	NULL
,	NULL
U.	NULL
,	NULL
Page	NULL
,	NULL
M.	NULL
,	NULL
Page	NULL
,	NULL
S.	NULL
,	NULL
Haas	NULL
,	NULL
M.	NULL
,	NULL
Gerling	NULL
,	NULL
A.	NULL
,	NULL
Kaltschmidt	NULL
,	NULL
C.	NULL
,	NULL
Neumann	NULL
,	NULL
F.	NULL
J.	NULL
,	NULL
Mackman	NULL
,	NULL
N.	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Arterioscler	NULL
.	NULL

Thromb	NULL
.	NULL

Vasc	NULL
.	NULL

Biol	NULL
.	NULL

17	NULL
,	NULL
1901-1909	NULL
4	NULL
-	NULL
Frostegard	NULL
,	NULL
J.	NULL
,	NULL
Wu	NULL
,	NULL
R.	NULL
,	NULL
Giscombe	NULL
,	NULL
R.	NULL
,	NULL
Holm	NULL
,	NULL
G.	NULL
,	NULL
Lefvert	NULL
,	NULL
A.	NULL
K.	NULL
and	NULL
Nilsson	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Arterioscler	NULL
.	NULL

Thromb	NULL
.	NULL

12	NULL
,	NULL
461-467	NULL
Received	NULL
26	NULL
May	NULL
1998/2	NULL
October	NULL
1998	NULL
;	NULL
accepted	NULL
5	NULL
November	NULL
1998	NULL
14	NULL
15	NULL
16	NULL
17	NULL
18	NULL
31	NULL
32	NULL
33	NULL
34	NULL
35	NULL
36	NULL
37	NULL
38	NULL
39	NULL
40	NULL
41	NULL
42	NULL
43	NULL
44	NULL
Uyemura	NULL
,	NULL
K.	NULL
,	NULL
Demer	NULL
,	NULL
L.	NULL
L.	NULL
,	NULL
Castle	NULL
,	NULL
S.	NULL
C.	NULL
,	NULL
Jullien	NULL
,	NULL
D.	NULL
,	NULL
Berliner	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Gately	NULL
,	NULL
M.	NULL
K.	NULL
,	NULL
Warrier	NULL
,	NULL
R.	NULL
R.	NULL
,	NULL
Pham	NULL
,	NULL
N.	NULL
,	NULL
Fogelman	NULL
,	NULL
A.	NULL
M.	NULL
and	NULL
Modlin	NULL
,	NULL
R.	NULL
L.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

97	NULL
,	NULL
2130-2138	NULL
Ohlsson	NULL
,	NULL
B.	NULL
G.	NULL
,	NULL
Englund	NULL
,	NULL
M.	NULL
C.	NULL
,	NULL
Karlsson	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
Knutsen	NULL
,	NULL
E.	NULL
,	NULL
Erixon	NULL
,	NULL
C.	NULL
,	NULL
Skribeck	NULL
,	NULL
H.	NULL
,	NULL
Liu	NULL
,	NULL
Y.	NULL
,	NULL
Bondjers	NULL
,	NULL
G.	NULL
and	NULL
Wiklund	NULL
,	NULL
0	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

98	NULL
,	NULL
78-89	NULL
Stemme	NULL
,	NULL
S.	NULL
,	NULL
Faber	NULL
,	NULL
B.	NULL
,	NULL
Holm	NULL
,	NULL
J.	NULL
,	NULL
Wiklund	NULL
,	NULL
O.	NULL
,	NULL
Witztum	NULL
,	NULL
J.	NULL
L.	NULL
and	NULL
Hansson	NULL
,	NULL
G.	NULL
K.	NULL
(	NULL
1995	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.S.A.	NULL
92	NULL
,	NULL
3893-3897	NULL
Viora	NULL
,	NULL
M.	NULL
,	NULL
Straface	NULL
,	NULL
E.	NULL
,	NULL
Di	NULL
Genova	NULL
,	NULL
G.	NULL
,	NULL
Fattorossi	NULL
,	NULL
A.	NULL
,	NULL
Rivabeng	NULL
,	NULL
R.	NULL
,	NULL
Camponeschi	NULL
,	NULL
B.	NULL
,	NULL
Masella	NULL
,	NULL
R.	NULL
and	NULL
Malorni	NULL
,	NULL
W.	NULL
(	NULL
1997	NULL
)	NULL
Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

232	NULL
,	NULL
359-363	NULL
Caspar-Bauguil	NULL
,	NULL
S.	NULL
,	NULL
Saadawi	NULL
,	NULL
M.	NULL
,	NULL
Negre-Salvayre	NULL
,	NULL
A.	NULL
,	NULL
Thomsen	NULL
,	NULL
M.	NULL
,	NULL
Salvayre	NULL
,	NULL
R.	NULL
and	NULL
Benoist	NULL
,	NULL
H.	NULL
(	NULL
1998	NULL
)	NULL
Biochem	NULL
.	NULL

J	NULL
.	NULL

330	NULL
,	NULL
659-666	NULL
Dansky	NULL
,	NULL
H.	NULL
M.	NULL
,	NULL
Charlton	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
Harper	NULL
,	NULL
M.	NULL
M.	NULL
and	NULL
Smith	NULL
,	NULL
J.	NULL
D.	NULL
(	NULL
1997	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.S.A.	NULL
94	NULL
,	NULL
4642-4646	NULL
Daugherty	NULL
,	NULL
A.	NULL
,	NULL
Pure	NULL
,	NULL
E.	NULL
,	NULL
Delfel-Butteiger	NULL
,	NULL
D.	NULL
,	NULL
Chen	NULL
,	NULL
S.	NULL
,	NULL
Leferovich	NULL
,	NULL
J.	NULL
,	NULL
Roselaar	NULL
,	NULL
S.	NULL
E.	NULL
and	NULL
Rader	NULL
,	NULL
D.	NULL
J	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

100	NULL
,	NULL
1575-1580	NULL
Emeson	NULL
,	NULL
E.	NULL
E.	NULL
,	NULL
Shen	NULL
,	NULL
M.	NULL
L.	NULL
,	NULL
Bell	NULL
,	NULL
C.	NULL
G.	NULL
and	NULL
Qureshi	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
Am	NULL
.	NULL

J.	NULL
Pathol	NULL
.	NULL

149	NULL
,	NULL
675-685	NULL
Gupta	NULL
,	NULL
S.	NULL
,	NULL
Pablo	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
Jiang	NULL
,	NULL
X.	NULL
,	NULL
Wang	NULL
,	NULL
N.	NULL
,	NULL
Tall	NULL
,	NULL
A.	NULL
R.	NULL
and	NULL
Schindler	NULL
,	NULL
C.	NULL
(	NULL
1997	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

99	NULL
,	NULL
2752-2761	NULL
Drew	NULL
,	NULL
A.	NULL
F.	NULL
and	NULL
Tipping	NULL
,	NULL
P.	NULL
G.	NULL
(	NULL
1995	NULL
)	NULL
Atherosclerosis	NULL
118	NULL
,	NULL
181-189	NULL
Zhou	NULL
,	NULL
X.	NULL
,	NULL
Stemme	NULL
,	NULL
S.	NULL
and	NULL
Hansson	NULL
,	NULL
G.	NULL
K.	NULL
(	NULL
1996	NULL
)	NULL
Am	NULL
.	NULL

J.	NULL
Pathol	NULL
.	NULL

149	NULL
,	NULL
359-366	NULL
Emeson	NULL
,	NULL
E.	NULL
E.	NULL
and	NULL
Shen	NULL
,	NULL
M.	NULL
L.	NULL
(	NULL
1993	NULL
)	NULL
Am	NULL
.	NULL

J.	NULL
Pathol	NULL
.	NULL

142	NULL
,	NULL
1906-1915	NULL
Fyfe	NULL
,	NULL
A	NULL
.	NULL

1.	NULL
,	NULL
Qiao	NULL
,	NULL
J.	NULL
H.	NULL
and	NULL
Lusis	NULL
,	NULL
A.	NULL
J	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

94	NULL
,	NULL
2516-2520	NULL
Hansson	NULL
,	NULL
G.	NULL
K.	NULL
,	NULL
Holm	NULL
,	NULL
J.	NULL
,	NULL
Holm	NULL
,	NULL
S.	NULL
,	NULL
Fotev	NULL
,	NULL
Z.	NULL
,	NULL
Hedrich	NULL
,	NULL
H.	NULL
J.	NULL
and	NULL
Fingerie	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.S.A.	NULL
88	NULL
,	NULL
10530-10534	NULL
Roselaar	NULL
,	NULL
S.	NULL
E.	NULL
,	NULL
Schonfeld	NULL
,	NULL
G.	NULL
and	NULL
Daugherty	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

96	NULL
,	NULL
1389-1394	NULL
Nilsson	NULL
,	NULL
J.	NULL
,	NULL
Calara	NULL
,	NULL
F.	NULL
,	NULL
Regnstrom	NULL
,	NULL
J.	NULL
,	NULL
Hultgardh-Nilsson	NULL
,	NULL
A.	NULL
,	NULL
Ameli	NULL
,	NULL
S.	NULL
,	NULL
Cercek	NULL
,	NULL
B.	NULL
and	NULL
Shah	NULL
,	NULL
P.	NULL
K.	NULL
(	NULL
1997	NULL
)	NULL
J	NULL
.	NULL

Am	NULL
.	NULL

Coll	NULL
.	NULL

Cardiol	NULL
.	NULL

30	NULL
,	NULL
1886-1891	NULL
Ross	NULL
,	NULL
R.	NULL
(	NULL
1993	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
362	NULL
,	NULL
801-809	NULL
Wick	NULL
,	NULL
G.	NULL
,	NULL
Schett	NULL
,	NULL
G.	NULL
,	NULL
Amberger	NULL
,	NULL
A.	NULL
,	NULL
Kleindienst	NULL
,	NULL
R.	NULL
and	NULL
Xu	NULL
,	NULL
Q	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
16	NULL
,	NULL
27-33	NULL
Stemme	NULL
,	NULL
S.	NULL
and	NULL
Hansson	NULL
,	NULL
G.	NULL
K.	NULL
(	NULL
1994	NULL
)	NULL
Coron	NULL
.	NULL

Artery	NULL
Dis	NULL
.	NULL

5	NULL
,	NULL
216-222	NULL
Basuerle	NULL
,	NULL
P.	NULL
A.	NULL
and	NULL
Henkel	NULL
,	NULL
T.	NULL
(	NULL
1994	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

12	NULL
,	NULL
141-179	NULL
Jain	NULL
,	NULL
J.	NULL
,	NULL
Loh	NULL
,	NULL
C.	NULL
and	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Curr	NULL
.	NULL

Opin	NULL
.	NULL

Immunol	NULL
.	NULL

7	NULL
,	NULL
333-342	NULL
Maniatis	NULL
,	NULL
T.	NULL
(	NULL
1997	NULL
)	NULL
Science	NULL
278	NULL
,	NULL
818-819	NULL
Négre-Salvayre	NULL
,	NULL
A.	NULL
,	NULL
Paillous	NULL
,	NULL
N.	NULL
,	NULL
Dousset	NULL
,	NULL
N.	NULL
,	NULL
Bascoul	NULL
,	NULL
J.	NULL
and	NULL
Saivayre	NULL
,	NULL
R.	NULL
(	NULL
1992	NULL
)	NULL
Photochem	NULL
.	NULL

Photobiol	NULL
.	NULL

§§	NULL
,	NULL
197-204	NULL
Kanno	NULL
,	NULL
T.	NULL
and	NULL
Sigbenlist	NULL
,	NULL
U	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

157	NULL
,	NULL
5277-5283	NULL
Kelly	NULL
,	NULL
K.	NULL
and	NULL
Siebenlist	NULL
,	NULL
U	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Curr	NULL
.	NULL

Opin	NULL
.	NULL

Immunol	NULL
.	NULL

7	NULL
,	NULL
327-332	NULL
Kahn-Perles	NULL
,	NULL
B.	NULL
,	NULL
Lipcey	NULL
,	NULL
C.	NULL
,	NULL
Lecine	NULL
,	NULL
P.	NULL
,	NULL
Olive	NULL
,	NULL
D.	NULL
and	NULL
Imbert	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

212	NULL
,	NULL
21774-21783	NULL
Pimentel-Muinos	NULL
,	NULL
F.	NULL
X.	NULL
,	NULL
Mazana	NULL
,	NULL
J.	NULL
and	NULL
Fresno	NULL
,	NULL
M.	NULL
(	NULL
1995	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

25	NULL
,	NULL
179-186	NULL
Yu	NULL
,	NULL
X.	NULL
P.	NULL
,	NULL
Bellido	NULL
,	NULL
T.	NULL
and	NULL
Manolagas	NULL
,	NULL
S.	NULL
C.	NULL
(	NULL
1995	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.S.A	NULL
92	NULL
,	NULL
10990-10994	NULL
Brand	NULL
,	NULL
K.	NULL
,	NULL
Page	NULL
,	NULL
S.	NULL
,	NULL
Rogler	NULL
,	NULL
G.	NULL
,	NULL
Bartsch	NULL
,	NULL
A.	NULL
,	NULL
Brand	NULL
!	NULL

,	NULL
R.	NULL
,	NULL
Knuechel	NULL
,	NULL
R.	NULL
,	NULL
Page	NULL
,	NULL
M.	NULL
,	NULL
Kaltschmidt	NULL
,	NULL
C.	NULL
,	NULL
Baguerle	NULL
,	NULL
P.	NULL
A.	NULL
and	NULL
Neumeier	NULL
,	NULL
D.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

97	NULL
,	NULL
1715-1722	NULL
Maziere	NULL
,	NULL
C.	NULL
,	NULL
Auciair	NULL
,	NULL
M.	NULL
,	NULL
DJavaheri-Mergny	NULL
,	NULL
M.	NULL
,	NULL
Packer	NULL
,	NULL
L.	NULL
and	NULL
Maziere	NULL
,	NULL
J.	NULL
C.	NULL
(	NULL
1996	NULL
)	NULL
Biochem	NULL
.	NULL

Mol	NULL
.	NULL

Biol	NULL
.	NULL

Int	NULL
.	NULL

39	NULL
,	NULL
1201-1207	NULL
Schackelford	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
Misra	NULL
,	NULL
U.K.	NULL
,	NULL
Floring-Casteel	NULL
,	NULL
K.	NULL
,	NULL
Thai	NULL
,	NULL
S.	NULL
F.	NULL
,	NULL
Pizzo	NULL
,	NULL
S.	NULL
V.	NULL
and	NULL
Adams	NULL
,	NULL
D.	NULL
0	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270	NULL
,	NULL
3475-3478	NULL
Ares	NULL
,	NULL
M.	NULL
P.	NULL
,	NULL
Kallin	NULL
,	NULL
B.	NULL
,	NULL
Eriksson	NULL
,	NULL
P.	NULL
and	NULL
Nilsson	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Arterioscler	NULL
.	NULL

Thromb	NULL
.	NULL

Vasc	NULL
.	NULL

Biol	NULL
.	NULL

15	NULL
,	NULL
1584-1590	NULL
Jovinge	NULL
,	NULL
S.	NULL
,	NULL
Ares	NULL
,	NULL
M.	NULL
P.	NULL
,	NULL
Kailin	NULL
,	NULL
B.	NULL
and	NULL
Nilsson	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
Arterioscler	NULL
.	NULL

Thromb	NULL
.	NULL

Vasc	NULL
.	NULL

Biol	NULL
.	NULL

16	NULL
,	NULL
1573-1579	NULL
May	NULL
,	NULL
M.	NULL
J.	NULL
and	NULL
Ghosh	NULL
,	NULL
S.	NULL
(	NULL
1998	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
19	NULL
,	NULL
80-88	NULL
Matsumura	NULL
,	NULL
T.	NULL
,	NULL
Sakai	NULL
,	NULL
M.	NULL
,	NULL
Kobori	NULL
,	NULL
S.	NULL
,	NULL
Biwa	NULL
,	NULL
T.	NULL
,	NULL
Takemura	NULL
,	NULL
T.	NULL
,	NULL
Matsuda	NULL
,	NULL
H.	NULL
,	NULL
Hakamata	NULL
,	NULL
H.	NULL
,	NULL
Horiuchi	NULL
,	NULL
S.	NULL
and	NULL
Shichirl	NULL
,	NULL
M.	NULL
(	NULL
1997	NULL
)	NULL
Arterioscler	NULL
.	NULL

Thromb	NULL
.	NULL

Vasc	NULL
.	NULL

Biol	NULL
.	NULL

17	NULL
,	NULL
3013-3020	NULL
Kusuhara	NULL
,	NULL
M.	NULL
,	NULL
Chait	NULL
,	NULL
A.	NULL
,	NULL
Cader	NULL
,	NULL
A.	NULL
and	NULL
Berk	NULL
,	NULL
B.	NULL
C.	NULL
(	NULL
1997	NULL
)	NULL
Arterioscler	NULL
.	NULL

Thromb	NULL
.	NULL

Vase	NULL
.	NULL

Biol	NULL
.	NULL

17	NULL
,	NULL
141-148	NULL
Escargueil-Blanc	NULL
,	NULL
1.	NULL
,	NULL
Salvayre	NULL
,	NULL
R.	NULL
and	NULL
Négre-Salvayre	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
FASEB	NULL
J	NULL
.	NULL

8	NULL
,	NULL
1075-1080	NULL
Auge	NULL
,	NULL
N.	NULL
,	NULL
Andrieu	NULL
,	NULL
N.	NULL
,	NULL
Négre-Saivayre	NULL
,	NULL
A.	NULL
,	NULL
Thiers	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
Levade	NULL
,	NULL
T.	NULL
and	NULL
Salvayre	NULL
,	NULL
R.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271	NULL
,	NULL
19251-19255	NULL
Schmitt	NULL
,	NULL
A.	NULL
,	NULL
Néegre-Salvayre	NULL
,	NULL
A.	NULL
,	NULL
Troly	NULL
,	NULL
M.	NULL
,	NULL
Valdiguié	NULL
,	NULL
P.	NULL
and	NULL
Saivayre	NULL
,	NULL
R.	NULL
(	NULL
1995	NULL
)	NULL
Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
1256	NULL
,	NULL
284-292	NULL
Chiu	NULL
,	NULL
B.	NULL
,	NULL
Viira	NULL
,	NULL
E.	NULL
,	NULL
Tucker	NULL
,	NULL
W.	NULL
and	NULL
Fong	NULL
,	NULL
1	NULL
.	NULL

W.	NULL
(	NULL
1997	NULL
)	NULL
Circulation	NULL
96	NULL
,	NULL
2144-2148	NULL

